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Abstract
In 2006, Massachusetts passed the Massachusetts Life Science Initiative earmarking $1 
billion for the development of the life sciences, particularly in the feild of stem cells. This IQP 
seeks to characterize the economic climate surrounding this initiative by looking at the actions 
taken by other similar initiatives taken by other states. The report will then critique the actions 
taken thus far and provide a set of reccommendations for future expenditures.
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Project Objectives
The goals of this Interactive Qualifying Project (IQP) were to study and analyse the 
economic potential of stem cell research and application, to develop an unbiased plan for the 
investment of the $1 billion set aside by the Massachusetts Legislature for the Massachusetts 
Life Sciences Initiative (MLSI) and to provide the community and general public with a road 
map of the current layout of stem cell research and application. Our findings indicate that stem 
cell research in the United States may have been hindered by restrictions placed on the 
funding of stem cell lines by the federal government. Consequently, the state governements 
have put forward money in the form of initiatives in order to attract stem cell research and 
industry so that the state may gain the benefits of this promising technology. The MLSI, 
passed in 2006, set aside $1 billion in funding for the life sciences. Part of this initiative is 
intended for use in stem cell research and related industry. Most research companies based 
solely on stem cell research are not making money and have partnered with pharmaceutical 
companies to continue research. Phamaceutical companies are attracted by potential products 
and treatements to be developed in the future. Although no specific products have been 
marketed, treatments, such as bone marrow transplant, which utilize the stem cells of the 
patient or a specific donor have been successful. Stem cell transport has been taken up by most 
biologic transport companies which are established both nationally and internationally. 
Storage, however, is a growing industry that has only begun to be explored. Massachusetts has 
set aside part of the MLSI to create a national stem cell bank and to create the first human 
embryonic stem cell (hESC) registry.
6
Methodology
The approach to gather information and analyze the data acquired for this report was bro-
ken up into four main areas: research, interviews, company comparisons, and state comparisons. 
The initial research was broken up into three main categories: science, legislation, and econom-
ics. The basic science behind stem cells was researched through journals, websites, and text-
books. Legislative background was pulled from journals, websites, and public documents. A 
working understanding of economics came from journals, stocks, company profiles, and financial 
reports. This initial background was supplemented through interviews with politicians, life sci-
ence employees, and venture capitalists. 
From all of this information, methods of comparing companies and states were put to-
gether. Companies were broken down into four sub-categories for easier comparison: large 
pharmaceuticals, small pharmaceuticals/start-up companies, research companies, and small busi-
ness clusters. States were broken down into three sub-categories: legislation regarding stem cell 
research and restrictions, state initiatives with significant financial investments focused on the 
life sciences, and companies located within each state.
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Glossary of Abbreviations*
Name Abbreviation
Interactive Qualifying Project IQP
Massachusetts Life Science Initiative MLSI
Human Embryonic Stem Cells hESCs
Embryonic Stem Cells ES cells
Fetal Stem Cells FSCs
Adult Stem Cells ASCs
Umbilical Cord Stem Cells UCSCs
National Institutes of Heatlth NIH
Food and Drug Administration FDA
Neural Stem Cells NSCs
United States Patent and Trademarks Office USPTO
Material Transfer Agreement MTA
Wisconsin Alumni Research Foundation WARF
New Jersey State Stem Cell Initiative NJSCI
Updated Economic Benefits of the New Jersey Stem Cell Capital Projects and 
Research Bonds Act
New Jersey 
Report
Gross Domestic Product GDP
New Jersey Cord Blood Bank NJCBB
California Institute for Regenerative Medicine CIRM
University of Wisconsin UW
Wisconsin Technology Council Tech Council
National Stem Cell Bank NSCB
Medical Doctor MD
University of Connecticut UConn
Illinois Department of Public Health IDPH
Illinois Regenerative Medicine Institute IRMI
Maryland Technology Development Corporation TEDCO
Maryland Stem Cell Research Fund MSCRF
Innovative, Developmental, or Exploratory Activities IDEA
Massachusetts Life Science Center MLSC
University of Massachusetts Medical School UMMS
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* Items are listed in order of appearance in text.
Name Abbreviation
Induced Pluripotent Stem Cells iPSCs
Doctor of Philosophy PhD
Worcester Polytechnic Institute WPI
California State University Program for Education and Research in Biotechnology CSUPERB
Massachusetts Institute of Technology MIT
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Chapter 1: Stem Cells
Currently, stem cell research and related treatments hold enormous promise for the curing 
of debilitating diseases such as spinal cord injury, Parkinson’s disease, diabetes and many other 
cell-based illness. Stem cells are categorized based on defining characteristics and the sources 
from which they are obtained. Although not all types of stem cells are used in current research, it 
is important to first gain an overall understanding of the terminology used. Then, more detail can 
be given to the specific stem cells used and the research currently being done.
Characteristics of Stem Cells
Stem cells are defined by their two unique characteristics: the ability to remain undifferen-
tiated and their level of potency. An undifferentiated cell is a cell that has not developed into a 
specific cell type, such as a neuron or a red blood cell, and is capable of self-renewal. Stem cells 
will retain their undifferentiated state in order to create more tissue based on the needs of the or-
gan. This allows the cell to be programmed to develop into another specialized tissue or organ of 
the body depending on the conditions it encounters. Stem cells divide to form two cells. One is 
called a daughter cell and it remains a stem cell. The second proliferates and then differentiates 
into the type of cells needed in the surrounding environment. (Cooper, 2007) Potency refers to 
the level of differentiation already undergone by the initial stem cell. Depending on the potency, 
a stem cell could only differentiate into a single type of cell, such as muscle stem cells, which 
only become muscle cells, or hundreds of types of cells, such as the cell that is formed from the 
fertilization of an egg, which will differentiate into every cell of the organism.
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There are five levels of potency: totipotent, pluripotent, multipotent, oligopotent and unipo-
tent. Totipotent stem cells can differentiate into literally every type of cell and tissue found in the 
organism. These cells are only found in embryos less than five days old. Pluripotent stem cells 
can differentiate into almost every type of cell and tissue in the organism but are limited based on 
what layer of the blastocyst they are apart of. Pluripotent cells are only found in embryos five to 
seven days old. These cells are no longer considered totipotent because the inner cell mass, the 
embryoblast, cannot differentiate into cells of the placenta and the outer cell layer, the tropho-
blast, can only differentiate into cells of the placenta. Multipotent stem cells can differentiate into 
many types of cells and tissues but only those within a closely related family of cells. For exam-
ple, a hematopoietic cell, a blood stem cell, can develop into several types of blood cells but can-
not develop into a muscle cell or a nerve cell. Oligopotent stem cells are even more specialized 
so that they can only differentiate into a few types of cells, such as vascular stem cells,  which 
only differentiate into endothelial or smooth muscle cells. Unipotent stem cells can only differen-
tiate into one type of cell or tissue. As mentioned above, muscle stem cells are considered unipo-
tent because they only differentiate into muscle cells. (Stem Cell Information, 2001)
These are the characteristics that make stem cells so promising. If the differentiation of the 
cells can be externally controlled, then the therapist can cause the cells to re-grow damaged tis-
sues, such as muscles or nerves, that don’t normally regenerate after injury or in the case of cer-
tain illnesses.
Sources of Stem Cells
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Stem cells are drawn from four sources: the inner cell mass of a blastocyst, the fetal and 
adult body, and the umbilical cord of newborns. (International Society for Stem Cell Research, 
2008) 
Stem cells originating from the inner cell mass, or embryoblast, of a blastocyst are called 
embryonic stem cells (ES cells). The blastocyst is the fourth stage in development of the embryo 
usually forming four or five days after fertilization and lasting until the sixth or seventh day. The 
blastocyst is made up of between 100 and 150 cells divided into two layers, the trophoblast and 
the embryoblast. The trophoblast forms the outer layer of the blastocyst and is made up of be-
tween 80 and 120 cells. This layer will eventually form the placenta. The embryoblast, consisting 
of 20 to 30 cells is the primary source of ES cells. (Marieb, 2007) This is done by inserting a sy-
ringe or pipet into the blastocyst and gently siphoning out the embryoblast. ES cells can also be 
obtained from earlier stages of embryonic development, such as at the 8-cell stage, but as this 
results in many fewer cells per extraction, this is rarely done. (Cooper, 2007) (See Figure 1.1) As 
hinted at, the extraction of ES cells from the blastocyst terminates further development. The ad-
vantages and disadvantages of ES cells from a research perspective will be gone over in more 
detail in the Current Areas of Research and Ethics sections as well as later in this section.
Undifferentiated cells found throughout the body of the organism in tissues such as bone 
marrow and skin are called fetal stem cells and adult stem cells (FSCs and ASCs) depending on 
the age of the organism from which they are extracted. (International Society for Stem Cell Re-
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search, 2008) FSCs are extracted from the organs and tissues of the fetus as well as fetal cord 
blood, baby dental pulp, and amniotic fluid. These cells are hard to distinguish from ASCs and 
are not used to great extent in therapeutic research and so will not be discussed further due to 
their controversial source, namely aborted fetuses. However, research continues to show that 
there are differences that could lead to more distinct classification in the future. (Vaziri, 1994) 
Most fully differentiated cells in adult animals are no longer capable of dividing. Therefore, in 
Figure 1.1: A diagram showing the progression of cells from a totipotent to a unipotent state detailing 
the extraction of ES cells.
13
almost every tissue of the body, ASCs are present to maintain and repair. In this capacity, ASCs 
last throughout the lifetime of the organism and are essential for the continued function of almost 
every organ. ASCs are further classified based on the families of cells into which they develop. 
For example, hematopoietic stem cells give rise to all types of red blood cells, white blood cells, 
and platelets, whereas epidermal stem cells undergo three to six divisions, called transit amplify-
ing, before differentiating into absorptive epithelial cells, goblet cells, and enteroendocrine cells. 
(Cooper, 2007) (See Figure 1.2) As ASCs are found throughout the body, they can be extracted 
from whichever tissue is the topic of study and are therefore more targeted to diseases or disor-
ders that affect a specific organ or tissue. These applications will be discussed in more detail in 
the Current Areas of Research section. Advantages and disadvantages will be discussed in more 
detail later in this section.
Stem cells isolated from the umbilical cord blood of newborns are simply called umbilical 
cord stem cells (UCSCs). UCSCs are very similar to hematopoietic stem cells in that they fulfill 
the role of replenishing the blood cells of the umbilical cord and placenta. The use of these cells 
is that they are easy to extract and store providing an untainted stock from which to draw on. 
During the treatment of some cancers or diseases, the bone marrow is eradicated and needs to be 
reestablished quickly in order for the immune system to resume proper function. A stored sample 
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of UCSCs from the patients umbilical cord would provide a perfect match when a donor proves 
hard to find. Also, stored UCSCs from an unrelated donor can be used. Very little further re-
search is being done with these cells but they will be discussed later as pertaining to stem cell 
storage.
Despite the diverse sources, the majority of research that is undergoing now uses embry-
onic and adult stem cells. There exist advantages and disadvantages for both embryonic and adult 
stem cells. ES cells can develop into the three types of tissues: ectoderm, mesoderm and endo-
derm, which can develop into all other kinds of cells in the body. Endoderm can develop into 
Figure 1.2: A diagram detailing the differentiation of a hematopoietic stem cell. Source: Cooper, 2007
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pancreas, lungs, liver and other organs. Mesoderm can become blood, muscle and connective 
tissue. Ectoderm can develop into neurons, sensory nodes and others. (Marieb, 2007) ASCs are 
less potent than ES cells, therefore their potential application in the medical field is limited to the 
family of cells to which they belong. However, since ASCs are found in almost every tissue of 
the body, specific researches could remove this limitation. Because ES cells are only found in 
embryos, there are fewer viable cell lines available for research whereas ASCs, although harder 
to extract initially, are available in any living organism and can be isolated much more readily. 
However, ASCs’ greatest advantage over ES cells is that they do not cause as much ethical con-
troversy . For ES cells, the most prominent issue is that the harvesting of ES cells from fetal tis-
sue involves the destruction of the human embryo. This issue will be discussed in much greater 
detail in the Ethics section. Because of the potency of stem cells, many physicians and research-
ers are striving to apply them to different treatments, including Parkinson’s disease, spinal cord 
injury, myocardial disease, diabetes, hemophilia, sickle cell anemia and many other cell-related 
diseases.
Current Areas of Research
Because of the great promise of stem cells, this being that their applications could be limit-
less, research involving stem cells is as vast and diverse as the cells themselves. For the sake of 
brevity, this report will focus on six of the most promising and prominent research areas, which 
include: gene therapy, treatment of Parkinson’s disease, correction of spinal cord injuries, treat-
ment of diabetes, therapy of myocardial diseases, and treatment of sickle cell anemia.
Gene Therapy
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Only non-embryonic human stem cells have been used in the study of cell-based gene ther-
apy but scientists have started exploring the possibility of using hESCs in such therapies. 
Gene therapy is a very recent and experimental way to treat human diseases. Compared to 
traditional drug therapies which administrate chemicals synthesized outside the body, gene ther-
apy directs the patient’s own cells to produce and deliver a healing agent. Genetic engineering, 
which is the elimination or introduction of special genes to physically alter or supplement the 
function of an abnormal gene by providing a copy of a normal gene, is mainly used for three 
purposes: (1) to directly repair a gene, (2) to provide a gene that gives new functions, or (3) to 
regulate the activity of other genes (Stem Cell Information, 2001). 
Currently, there are about 180 gene therapy clinical trials in the US that are cell-based and 
75% of these trials use human stem cells, particularly hematopoietic stem cells to deliver trans-
genes into patients. Transgenes are genes or genetic materials that have been transferred naturally 
or by any of a number of genetic engineering techniques from one organism to another. The ma-
jor reason that stem cells are used in cell-based gene therapies is because of their ability to self-
renew which may decrease or eliminate the need for repeated administrations of the gene therapy 
(Stem Cell Information, 2001). 
Of all the types of stem cells, hematopoietic stem cells are most commonly used. This is 
because they can easily be removed from the body through the blood or adult bone marrow or 
the umbilical cord blood of newborns. Moreover, it is easy to identify and manipulate them in the 
laboratory and then return them to patients via injection. The other advantage that hematopoietic 
stem cells have is their ability to migrate to many different places in the human body, especially 
the bone marrow, the liver, and the spleen, all of which can be strategic locations for localized 
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delivery of therapeutic agents for disorders that are not related to the blood system such as im-
munodeficiency disease. (Stem Cell Information, 2001).
With the development of therapeutic medicine, more and more scientists have  embraced 
gene therapy; however, certain groups of people still hold objections to it because of the failure 
that occurred in 1999. At the University of Pennsylvania’s Institute of Human Gene Therapy in 
Philadelphia, a patient, Jesse Gelsinger, died from a reaction to gene therapy. He accepted the 
experimental treatment that had the potential to cure his disease. Unfortunately, the experiment 
failed and he was killed. After his death, the Food and Drug Administration (FDA) and NIH 
launched investigations of the University of Pennsylvania studies. Later the FDA quickly shut 
down all the clinical gene transfer trials at the University of Pennsylvania. The FDA also stopped 
gene therapy trials in a great number of other research institutes, started launching random in-
spections of 70 clinical trials, and instituted new reporting (Stem Cell Information, 2001).
Since then, the number of researches on gene therapy has largely decreased because the 
public has lost confidence in it.
Parkinson’s disease
Parkinson’s disease is a type of brain disorder. It manifest when certain neurons in the sub-
stantia nigra of the brain die or become impaired. These neurons normally produce dopamine 
which is a critical chemical in the brain that allows smooth and coordinated function of the 
body’s muscles and movement. However, when approximately eight percent of those dopamine-
producing cells are damaged, the symtoms of Parkinson’s disease start to become evident (Na-
tional Parkinson Foundation, 2007).
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In the United States, Parkinson’s disease is one of the most common neurodegenerative 
disorders that affect at least 500,000 people (National Institute of Neurological Disorders, 2006). 
Moreover, about 50,000 people are diagnosed as Parkinson’s disease annually. Therefore, each 
year a huge amount of money is invested in the related research to find out a cure for it. For vari-
ous reasons, traditional treatments that focused on surgical therapy and medication failed to ef-
fectively treat this disease (National Parkinson Foundation, 2007). 
Stem cells offer hope to provide a potential treatment for Parkinson’s disease. Researchers 
have been exploring the effective way to transplant stem cells into the target positions of the 
brain where dopamine is needed. They cultivate stem cells from bone marrow and program them 
to be similar to those dopamine-producing neurons. Because Parkinson’s Disease is caused by 
the dysfunction of dopamine-producing neurons in the thalamus and nothing else, it is one of the 
most likely beneficiaries of stem cell research (Borthwick, 2008).
Spinal cord injury
There are over 11,000 Americans who suffer from spinal cord injury annually, mostly from 
traffic accidents. Spinal cord injuries cause the loss of ability to regenerate myelin, which is a 
layer that insulates nerve fibers that transmit signals from the brain, resulting in paralysis. The 
effects can be permanent since myelin cells are not able to regenerate on their own. (Society for 
Neuroscience, 2004)
Recently, Hans Keirstead and his coworkers in Reeve-Irvine Research Center used a hu-
man ES stem cell treatment to successfully restore the insulating layer for neurons in rats after 
they had been injured for seven days. The restored functions include the recovery of certain mo-
tor skills. However, the same treatment failed to treat rats with the same injury but with a longer 
19
time span for about ten months. This research suggested that neural stem cells (NSCs) bring hope 
in the treatment for spinal cord injuries, but most possibly only be effective for a certain period 
of time after the injury.
Diabetes
Diabetes is a disease in which the body fails to produce or properly use insulin, a hormone 
that is essential to convert starches, sugar and other types of carbohydrates into energy essential 
for the human body. Currently in the United States, about 7.8% of the population is suffering 
from diabetes (American Diabetes Association, 2009). 
There are two types of diabetes: in type I diabetes, the patients’ bodies fail to produce insu-
lin and this lack of production generally results from the autoimmune destruction of pancreatic 
β-cells. If patients cannot receive treatment, they can suffer from a large number of other dis-
eases, including nerve damage, kidney damage, heart disease etc. Currently, most of the patients 
rely on daily injection of insulin to maintain its level in their body or use organ transplant which 
is the best way to cure it. However, the pancreas allograft transplantation is greatly limited by the 
insufficient number of donations and the accompanying rejection by the host (American Diabetes 
Association, 2009). 
A recent study done in vitro used undifferentiated hESCs to demonstrate their differentia-
tion into pancreatic β-cells that produce insulin in human body. Stem cell treatment offers the 
hope of using such cell lines in cell replacement therapy for the treatment of type I diabetes in 
that it can differentiate into the essential pancreatic β-cells. However, isolating the pancreatic 
stem cells can be a very challenging task in that pancreas is a diverse organ consisting of multi-
ple types of cells that function together(Ball, 2003).
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Currently, NovoCell Inc. is a company that invested on the treatment of type I diabetes 
with the use of hESCs. The treatment includes the creation of insulin producing islet cells origi-
nated from human embryonic stem cells which can be transplanted into patients with type I dia-
betes later. The company also made success in the combination of this treatment with the cell en-
capsulation technique that used polyethylene glycol to cover the embryonic cell-derived islet 
cells and protect them from the immune system of the host. Therefore, this treatment stands out 
for two major advantages over other treatments for type I diabetes: no limitation on islet cell do-
nors because of the procedure to counter immune rejection and less cell injections is required 
(Pollack, 2008).
Myocardial diseases
Congestive heart failure is the ineffective pumping of the heart caused by the dysfunction 
of heart muscle cells that are usually caused by a heart attack, hypertension, or coronary artery 
disease. Many researches have been focusing on the use of stem cells to replace the damaged 
heart cells and therefore restore the heart’s function. All the recent studies have shown that stem 
cells have great potential to treat patients who have suffered from heart attack. Therefore, this 
brings great hope to future heart attack sufferers.
So far, the research using stem cells to restore damaged heart function have shown success 
in both rodent models and human clinical trials. At the Texas Heart Institute, fourteen dying pa-
tients with heart failure accepted stem cell treatment. Stem cells were collected from the bone 
marrow of those patients and then were injected back into them later. There was another group of 
patients that did not undergo the stem cell treatment. After about two months, compared to the 
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untreated group, the treated group could pump more blood and experienced less chest pain 
(Fischman, 2003).
Sickle cell anemia
Sickle cell anemia is the most common inherited blood disorder in the United States. It is a 
disease in which the body produces misshapen red blood cells that do not last as long as normal, 
round red blood cells and lead to anemia. The abnormal sickle cells pile up in the blood vessels, 
causing pain, anemia, infections, organ damage, and stroke. In the United States, there are ap-
proximately 80,000 people who have this inherited condition. There is no known cure other than 
stem cell transplantation at current stage.  (National Heart Lung and Blood Institute, 2008). 
Researchers at Memorial Sloan-Kettering Cancer Center devised a new way using stem-
cell based gene therapy that genetically reverses sickle cell anemia in the human cells. In this 
gene therapy, a viral vector was introduced in cell cultures of patients with sickle cell anemia to 
prevent the production of the abnormal hemoglobin which is the cause of sickle cell anemia. The 
researchers found that the newly formed red blood cells produced normal hemoglobin and sup-
pressed the production of the misshapen hemoglobin (Samakogly, 2005). 
Now Sickle cell disease can be cured by transplanting healthy hematopoietic stem cells 
from a donor. However, there exists a problem for most patients:  it is difficult to find a compati-
ble donor. Hopefully this difficulty can be solved in the near future.
Ethics*
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* For a well-thought out and detailed analysis of the ethical and moral implications of all stem cell types, please see “The Stem 
Cell Controversy” by Jessica Collins (02E023I)
With any type of research or treatment, there are always ethical implications to the actions 
taken. Stem cells, and more specifically hESCs, have formed the center of ethical controversy 
since their derivation in 1998. The heart of this debate is made up of several central questions. 
The most vehement arguments tend to stem from the moral status of the human embryo itself, 
and whether this status necessitates that it be protected under law. Further extrapolation from 
these questions brings into question the status of newly formed hES cells.
ASCs and UCSCs do not raise these same issues as they fall under the same ethical consid-
erations as donated blood or somatic cells. FSCs raise even greater ethical controversy because 
of the debate surrounding abortion in general. When this is merged with stem cell controversies, 
it creates ethical dilemmas not worth pursuing.
Convictions designating the moral status of the human embryo tend to follow three general 
trends. Some people believe that human life begins at the “moment of conception”, namely the 
point at which a sperm comes into contact with an egg. From a biological perspective, this is a 
misnomer as the genome is not fully established as a diploid until at least 24 hours after the 
sperm and egg merge. Another belief is that a person is gradually formed throughout the devel-
opment of the embryo into a fetus designating conception as merely the first stage along this de-
velopment. A third group believes that, although the human embryo is representative of human 
life, it may be taken for the sake of saving others. These viewpoints are flexible and so some in-
dividuals will adhere to more than one but, in general, people seem to agree with at least one of 
these viewpoints.
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Chapter 2: Economics
Since the 1970’s, stem cells have been advertised as a potential panacea to treat any and 
all illness. Due to the cell’s unlimited proliferation potential, researchers believe that stem cells 
can be used to treat a number of major diseases that are currently untreatable and cost the U.S. 
billions of dollars. Examples of such diseases include Parkinson’s disease, Alzheimer’s disease, 
diabetes, and spinal cord injuries, some of the most prevalent and expensive diseases within the 
United States. At present, there are no marketable stem cell products that have been released, and 
so the majority of stem cell companies are still in research stages.  Our task is to determine 
whether it is beneficial to invest into these researching individuals or to take a more indirect 
approach and support other aspects of the life sciences field. In order to create a beneficial 
economic stimulus to Massachusetts, the money that is to be invested must ideally cause a return 
either in the form of new jobs opportunities, large tax returns, or a profit from the investment. 
Therefore before we delve too much into the topic at hand let us become familiarized with how 
the business world of today works.
Patents
In the modern world, most companies cannot survive without the use of special licensing 
agreements, better known as patents. Patents are specific authorities conferred by the federal 
governement of a country given to an individual or company granting the sole right to make, use, 
or sell some invention. In the United States, a patent grants a monopoly to the inventor for 
twenty years with the only requirements for receiving a patent being that the idea must be novel, 
useful, and nonobvious, and the disclosure of the invention is part of the patent application in 
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such a way that it enables others to replicate it. If a patent application meets these criteria, the 
United States Patent and Trademarks Office (USPTO) must issue a patent. The issuance of a 
patent does not entitle the inventor to sell or use the invention. The regulation of products and 
devices has always rested with relevant state agencies. (Korobkin, 2006)
In the life sciences, these patents can take varous forms. The most commonly understood 
form is a patent on a physical invention taking the form of a product or device designed by the 
inventor. Another common form is a patent conferred on a material or substance created by the 
inventor. A lesser understood patent type is a process patent whereby an inventor can patent the 
process by which a material or product is prepared. This is incredibly important with stem cells 
since there are very few proven methods by which stem cells can be isolated and utilized in 
research. The final, most abstract from is an idea patent. This is the patenting of a pre-existing 
device, material, or process to a new application. For instance, if a researcher decides to use the 
method by which you isolate mouse hematopoietic stem cells to isolate primate mesenchymal 
stem cells, he or she may be able to patent it. Once a company has invented a new product or 
idea, they are able to patent their idea in order to claim the idea and be protected by patent law. 
However it is important to realize that all patents are not marketable products. A company may 
have hundreds of patents, but only three of them might be something that is marketable and will 
actually make money. By holding the exclusive rights to produce and sell the marketable product 
through a patent allows a company to make money off of the new deliverables.
Companies
Companies can be divided into two different groups; public and private. When a 
company is first created it is created by an individual or group of individuals and is considered a 
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private company as it is run by the founder(s) and is not obligated to release information on its 
private operations or management to the general public. These private startup companies then 
typically obtain money through private investors, such as venture capitalists, in order to obtain 
the funds necessary to run the company. Assuming that the company is able to survive its initial 
hurdles, the company then has the option of entering the public market as a public company. 
Once a company has “gone public”  then the company is able to sell stock. The larger the 
company, the more stock shares it will have; and the more successful the public perceives the 
company, the higher the worth of the stock itself. Therefore as a result the worth of a company is 
not necessarily determined by how much income or money that the company holds; instead, the 
company’s total assets are reviewed and the company’s worth is determined by the buying power 
of the public.
Investment Categories
After researching the possible avenues of investment, the number of different areas of 
possible investment has been narrowed down into eight different categories; large 
pharmaceuticals, start-up companies (which may include small start-up pharmaceutical 
companies, start-up research companies, or small medical device companies), small business 
clusters, transportation, storage, basic science, infrastructure, and private investment or venture 
capital. Within the provided list, stem cell research is tied to the categories of basic science, 
storage, and transportation. The other five categories are possible alternatives that can also be 
considered if it appears that investment into stem cell research is not advisable, or if the 
alternative strategies simply have a better projection of stimulating the economy. 
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The first of the alternative investment categories, large pharmaceutical companies are, as 
the name might suggest, large and well established companies that dabble in numerous areas of 
research and product development. These companies are more commonly known for their 
research into creating new marketable drugs, but they also have branches that create medical 
devices or medical instruments that are needed for medical procedures. With the large influence 
that these pharmaceutical companies have in the market, they are able to take advantage of the 
numerous branches of research and are able to have large net incomes from the product sales. 
Baxter International Inc and Wyeth are two examples of public large pharmaceuticals. The two 
companies have recorded revenues of 11.26 billion and 22.4 billion dollars respectively, and both 
have employee counts well over 47,000.*
Investment into large pharmaceutical companies should be made in a way that would 
persuade the companies into creating new facilities within Massachusetts. With their arrival there 
would both be short term and long term returns to the state. The immediate short term gains 
would be an increase of employment opportunities and increased tax returns to the state from 
residential taxes of employees that will move into Massachusetts, labor taxes from all the new 
employees of the facility, and company income taxes that will be very large as the revenue will 
be in the millions. Unfortunately as successful and stable as large pharmaceutical companies may 
seem, upon closer inspection it is a surprisingly fragile existence. While it is true that a large 
company is able to large net incomes in the billions, it is also true that the company has very 
large expenses. In order for the large pharmaceutical company to produce the large number of 
products to sell at market, they need to pay the expenses of creating and transporting that 
product. Therefore should for whatever reason the company fall even just 10% in their income, it 
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* Financial information was taken from the most recent Nasdaq publications.
may be enough so that the company is unable to support its expenses thus starting a downward 
spiral of job cuts or even factory closings. Due to the large and complex management that is 
required for the large company to exist disturbances, like the current economy, may cause what 
seemed to be a stable behemoth to fall instantly.
The second alternative category to stem cell research is small start-up companies. Unlike 
the before mentioned large pharmaceuticals, small companies do not make large revenues, and 
for the most part survive by collaborations with larger companies within its own field. When 
started up by an individual or individuals, the most pressing problem is for the founder(s) to find 
a way of funding the expenses of starting and then running the company to research or create the 
idea that they believe can be created. In most cases the company will seek private investors, also 
known as venture capitalists, or seek bank loans to obtain the necessary funds, and then work to 
make their idea into a reality. Unfortunately the majority of these companies are unable to bring 
their ideas to fruition and those who fail will eventually be closed down because they cannot 
continue to fund their research. For members of the group able to successfully market their ideas, 
they face competition against the larger companies that have much larger revenues to compete 
against. As a result some of these start-up companies will not aim to grow and compete with the 
already well established large companies, but may attempt to pursue what is known as ‘exit 
strategy’. This is an economic term defined as:
“A plan for disposing of a business and realizing the value of the investment 
made in it. The development of an exit strategy involves establishing the 
value of the business, identifying and selecting exit options, identifying and 
removing obstacles, and preparing and implementing a plan. Exit options 
include the sale of the business, merger, flotation or public listing, 
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management buy-out, franchising, family succession, ceasing to trade, or 
liquidation.” (BNET, 2009)
Suppose that a small start-up pharmaceutical is able to find a new protein or drug that they 
successfully patent. It is a very long and expensive process to then take this research and obtain 
all the necessary FDA approval; most researchers generalize this process to take about ten to 
fourteen years. The start-up pharmaceutical may not have the necessary funds to complete this 
task, and instead the company will be more inclined, especially if they were funded by venture 
capitalists, to have the company make use of an exit strategy to be incorporated by a larger 
company. Larger pharmaceutical companies have both the resources and expertise to simply buy 
the smaller company and invest the money necessary to see it to market. Through this manner the 
smaller company is quickly able to make a large amount of money, while the larger 
pharmaceutical company is able to hold the exclusive rights of producing the product and bring it 
to market. 
 A third alternative to investing into stem cells is to invest into small business clusters. 
Small business clusters are the collaboration of a number of small businesses to work together to 
reach new heights in research and product development. The money invested into this category is 
spent supplying devices and grant money to small companies that may not have the money to 
afford the research materials. Also as a added bonus, the companies will work together to achieve 
results that will be expedited by the free exchange of research and expertise. Thus, investment in 
a single company results in investment into multiple companies. Also, company clusters share 
resources, facilities, intellectual property, and research staff. This drastically cuts down the 
expenses of each company and allows any investment money to be used more efficiently.
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 The fourth and final alternative category is infrastructure. By allocating a fixed amount of 
money into the expansion of roadways, sewer systems, and other utilities, such as electricity and 
phone lines, the state is better prepared to absorb the influx of people, buildings, and traffic 
utilizing its resources. Investing into infrastructure can also be considered as investing into large 
companies, as large companies cannot be created without necessary infrastructure to sustain it. 
Infrastructure also includes the building of new facilities that will help to spur on collaboration, 
research, and expansion. Examples include laboratory and storage facilities that will help to curb 
up-front costs of larger companies moving into the state and smaller companies just getting 
started.
Research companies, especially ES cell research companies, closely resemble small 
startup companies in terms of size and monetary troubles, but the method of income for research 
companies are very different. Pharmaceutical companies make money by creating a number of 
new marketable products and use patents, also known as licensing agreements, to protect their 
marketable products. Also pharmaceutical companies work to develop new products and 
accessories for well used medical procedures and research, so they already have an established 
consumer base where the company will be able to make money from. Stem cell research 
companies are in a drastically different situation.   ES cell research is still mostly in its 
developmental stages, and so there are not many stem cell marketable products that have been 
released. In fact in the thirty and so years of research in the stem cell field, it was only on Jan 23, 
2009 (Cell News, 2009) that the Geron Corporation was the first research company to receive 
FDA approval to conduct clinical trials of ES cell treatment for minor spinal cord injuries. As a 
result, these research companies also use patents to help support themselves, but their patents 
focus more on procedures, methods, and research findings that they will receive money from. 
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Material transfer agreements (MTA) are liscences given out by these research companies that 
allow others to use their material patents for a price specified by the patent holder. 
A number of early research companies, such as Geron Corporation, Wisconsin Alumni 
Research Foundation (WARF), and John Hopkins University, hold the majority of general 
research patents. This is very beneficial for these established companies, but make it difficult for 
any new startup research companies or individual researchers to market new products. For 
researchers, the MTA is free but no marketable product can be derived from the research. All 
findings must remain academic and open to the public domain. For research companies, an initial 
charge, estimated around $250,000, is levied for the MTA and then annual fees are also charged 
for continued research. It is also important to know that these companies are unable to make a 
net profit. Geron Corporation is one of the earliest and more successful of the stem cell research 
companies, but the company itself is unable to make money (Refer to table 2.1). When viewing 
the 10-k financial reports from Geron, there is yet to be a year where the company has made a net 
profit. The general patents that Geron holds do bring in a set income, but even when 
supplemented with money from both private and public investors, the company is forced to 
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Table 2.1: Gerons expenses in Thousands of dollars
Geron 1996 1997 1998
Research and Development Expenses 14, 260 15, 139 15, 619
Net Loss 10, 687 9, 641 10, 832
Revenue from collaborative agreements 5, 235 7, 175 6, 706
Stock High 13.250 13.375 11.250
Number of Stock holders 166 424 728
spend large amounts of money on research in the hopes that they will be able to create a novel 
treatment that can deliver the promise that resides in stem cell research.
The last category is stem cell storage and transportation. Unfortunately transportation is a 
business that is already very well established by a number of different companies. Also due to 
the various additional fees and expenses caused by the crossing of state lines, it is very unlikely 
that investing into the field would bring much stimulus to the state. Stem cell storage however is 
a whole different story. At present there are only a handful of national cell storage companies 
meaning that it is still a relatively new and developing field.
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Chapter 3: State Initiatives
In order to determine the economic impact of each state’s legislative actions, we have to 
evaluate the initiatives put in place by each state and the projected economic benefits from each 
initiative. (See Figure 3.1) After determining the effectiveness of other states’ actions, the same 
analysis can be done for the actions that the Commonwealth of Massachusetts has taken, namely 
the MLSI. The information on state laws and financial commitments for life science research was 
collected using government websites, business journals, speeches, and various reports analyzing 
the possible outcomes of the state investment in stem cell research and facilities construction. 
This section of the study will evaluate all state’s initiatives following a chronological timeline of 
states passing legislature with financial components. 
Human stem cells are first isolated at Wisconsin University in November 1998 and their 
potential to create a vast range of treatments is superimposed on their controversial method of 
derivation. Two years later, it was necessary for the National Institutes of Health (NIH) to issue 
guidelines that regulate federal funding of stem cell research during the Clinton Administration. 
A year later (August 2001) President George W. Bush placed a hold on federal funding for stem 
cell research involving destruction of embryos.  NIH is responsible for tracking federal funds 
awarded for stem cell research that meets certain criteria:
“The derivation process (which begins with the destruction of the embryo) was 
initiated prior to 9:00 P.M. EDT on August 9, 2001. The stem cells must have 
been derived from an embryo that was created for reproductive purposes and was 
no longer needed. Informed consent must have been obtained for the donation of 
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the embryo and that donation must not have involved financial inducements.” 
(National Institutes of Health, U.S. Department of Health and Human Services, 
2009, 2009)  
Some states’ officials consider those federal restrictions as limiting to their state growth in 
educational and economic aspects. Regardless of federal policy, many state governors decide to 
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Figure 3.1: Timeline of State initiatives (Godoy, 2009)
create funding methods for stem cell research in addition to the NIH funding.   This decision is 
substantial for states with advanced biotechnology industries because they want to remain lead-
ers in this area at national and international levels. Another advantage of state life science initia-
tives is preventing biotechnology-related companies and scientists from relocating to other states 
or countries overseas.
New Jersey
In 2004, New Jersey becomes the first state to finance hESC research including cell lines 
prohibited by the Bush Administration. The Democrat governor Corzine considered New Jersey 
State funding as “an important step in our growing partnership with private industry to fund this 
promising and potentially life-saving science.” (State of New Jersey, 2004)
 The New Jersey State Stem Cell Initiative (NJSCI) was revised after the first report “Eco-
nomic Benefits of the New Jersey Stem Cell Research Initiative”  prepared by Joseph Seneca and 
Will Urving at Rutgers University for Office of the Governor in Sept. – Oct. 2005. In October 
2007 a new report was prepared for the New Jersey State Senate President Richard Codey by the 
same authors (See Table 3.1). “Updated Economic Benefits of the New Jersey Stem Cell Capital 
Projects and Research Bond Acts”  (New Jersey Report) explains in details the revised benefits 
from the newly signed initiative. 
The New Jersey Report outlines authorized expenditures of $270 million for construction 
and equipping of stem cell research and other biomedical facilities and $450 million in funds for 
on-going stem cell research, which means $120 million more than the infrastructure expenditures 
initially proposed and $220 million more than the original expenditures planned for research 
grants. Based on the revised calculations for projected benefits for the state generated from the 
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NJSCI, 7,766 job-years (one job-year is equal to one job lasting one year) will be created and 
they will generate a total of $475.3 million in income. An estimated $41.5 million in state and 
local taxes will be generated from the newly created employments. In addition to that $546.7 
million in Gross Domestic Product (GDP) will be generated that would not have been possible if 
the initiative was not in action. (Seneca, 2007)
In 2005 the creation of an umbilical cord blood and placental stem cell bank was planned. 
This investment was made as a result of the NJSCI, which makes this facility the first U.S. 
publicly funded stem cell bank. Two years later all operations of the New Jersey Cord Blood 
Bank (NJCBB) were taken over by a non-profit organization called Community Blood Services. 
This is the only public cord blood bank for the State of NJ.  (Community Blood Services, 2007)
California
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Table 3.1:  Two Combined Economic Impacts on New Jersey of $270 Million in Capital Expenditures and $450 
Million in Research Expenditures for Stem Cell and Other Biomedical Research Facilities (Current $)  - 
(Seneca, 2007)
Indicator Capital Expenditures 
($270 million) 
Research Expenditures 
($450 million) 
Total Expenditures ($720 
million) 
GDP $186.5 million $360.2 million $546.7 million
Employment 2,681
(job-years)
5,085
(job-years)
7,766
(job-years)
Income $ 153 million $322.6 million $475.3 million
State Taxes $6.6 million $13.1 million $19.7 million
Local Taxes $7.4 million $14.4 million $ 21.8 million
California is the first state to propose state funding for stem cell research but the proposi-
tion isn’t ratified until after the NJSCI. In November 2004 Californians approves Proposition 71, 
which states that nearly $3 billion general obligation bonds will be invested in stem cell research. 
The targeted institutions are universities and medical schools that are involved in stem cells pro-
grams. The funding is divided so that 90% is earmarked for research and 10% for facility crea-
tion. (See Figure 3.2 below)  The total bond cost with interest is estimated to be $5.4 billion 
(Baker, 2004) according to the authors of the “Economic Impact Analysis”  report. The analysis is 
based upon Proposition 71 and it estimates the financial benefits for the State of California as a 
result of the investment in stem cell research. The aforementioned report evaluated the initiative 
over 3 time periods for total length of 35 years. Years 1 to 5 will be used to finance research fa-
cilities ($300 million) and grants ($1.25 billion). Years 6 to 14 are planned for investment in re-
search with the remaining amount from the Initiative. This is also the time when the 30-year 
principal period begins. The final increment of time is years 15 to 35. It is intended to pay the 
entire principal and interest till the end of the period since the $3 billion Stem Cell Initiative will 
be spent by year 14. Reference the following figure (Figure 3.2) for breakdown of the Economic 
Costs of Proposition 71.
The California report is focused on four potential areas, where Economic Benefits are ex-
pected to be generated for the budget of the State of California. Even though different scenarios 
were discussed based on the overall therapeutic success of the stem cells research, the analysts 
concluded that even the worst case scenario will generate more benefits for the state and the 
communities of California than the investment. The first two areas of interest are the benefits 
generated by the investment made directly from Proposition 71 and by the additional economic 
activity of biotechnology in California. Primarily they will generate tax revenues from newly 
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created employment that will result in increased income taxes and sales taxes. The table (Table 
3.2) below lists the projected number of jobs created on average for each period of time. 
The third area researched is based on healthcare cost reduction resulting from new thera-
pies creation. Six diseases (stroke, heart attack, spinal cord injury, Parkinson’s Disease, Alz-
heimer’s disease, and insulin-dependent diabetes), which are most likely to be affected by stem 
cell therapeutics according to medical and scientific experts, are included in the study. The worst 
case scenario predicts that the stem cells research will reduce only 1% of the costs. This includes 
only mitigation of the 6 basic conditions or delaying the onset of some serious medical condi-
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Figure 3.2: Flowchart breaking down the distribution of funds for California Initiative.
tions. Savings for the state from this reduction of the healthcare cost are approximated to be $3.4 
billion (Baker, 2004) over the lifetime of the initiative. The table below (Table 3.3) lists the 
healthcare costs to Californians and to the State Budget together with each case’s projected sav-
ings.   
The final source of benefits for California comes from royalties that result from the Initia-
tive funding. A moderate scenario is considered to generate royalty revenue of $500 million 
(Baker, 2004) over the life of grant investment in universities and Medical Centers in California. 
Proposition 71 created the California Institute for Regenerative Medicine (CIRM). This 
agency is responsible for grants and loans that are provided for stem cell research and facilities. 
The grants and research awards that were granted in the past 3 years were oriented mainly to-
wards basic stem cell research, new faculty hiring, facility equipment and tools, and new stem 
cell lines. The most recent grants are targeted for therapy development. Multidisciplinary teams 
are funded by the CIRM to transfer the most promising basic stem cell research into clinical ap-
plications and possibly create treatments. (California Institute of Regenerative Medicine, 2009)
Business expansion in California is considered to be a result of new private investment 
attracted to the state. The focus is on potential private start-up companies to locate in California 
and generate tax revenues from the employees. Income taxes will be paid by workers; sales taxes 
will be paid by workers and the companies that are undertaking new research. (Baker, 2004)  The 
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Table 3.2: Projected number of jobs created during each time period.
Years 1 – 5 Years 6 – 14 Years 15 – 35 Total
Revenues Generated by 
Proposition 71 Spending 2,900 jobs/year 3,700 jobs/ year 0 jobs/year 47,000 job-years
Increased Biotechnology 
Investment in CA (2.5% 
industry augment)
2,400 jobs/year 7,500 jobs/year 11,000 jobs/year 313, 000 job-years
State initiative does not include plans for financing company creation or support certain 
companies with tax incentives.
Wisconsin
In November 2004, Wisconsin governor Jim Doyle announced that over the next few years 
the state is providing $750 million of combined public and private money for biotechnology, the 
majority of which will be focused on stem cell research. (Groves, 2004) The initiative includes 
$375 million for building a new research facility at the University of Wisconsin (UW) in Madi-
son  called Wisconsin Institute for Discovery. (Johnson, 2006) The interdisciplinary institute re-
ceived private funding of $100 million for its construction in addition to the state subsidiary. 
WARF, a non-profit organization, provided $50 million and another $50 million was donated by 
John and Tashia Morgridge. (Twohey, 2006) The state earmarked $105 million for investment in 
research and education activities related to regenerative medicine, molecular medicine, neurosci-
ence and cancer research at the UW Medical School and the Medical College of Wisconsin for 
stem cells. (Johnson, 2006) Finally, the Wisconsin state initiative will spend $134 million for ba-
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Table 3.3: Healthcare costs to California and projected savings
Case 1: Limited Thera-
peutic Success (1% sav-
ings) 
Case 2: Increased Thera-
peutic Success (2% sav-
ings) 
Case 3: Expanded Thera-
peutic Success (10% sav-
ings )
Direct Medical Cost and Lost 
Work Time Costs to Califor-
nians 
$ 1,316 billion $ 1,316 billion $ 1,316 billion 
Impact of Savings $11 billion $ 23 billion $ 114 billion 
Direct Medical, Lost Work 
Time, and Nursing Home 
Cost to State Budget 
$ 390 billion $ 390 billion $ 390 billion 
Impact of Savings $ 3.4 billion $ 6.9 billion $ 34.4 billion 
sic science research and the rest of the money is planned for specific research fields such as stem 
cell related research.
The projected jobs that will be created as a result of the initiative is estimated to be 27, 000 
according to the Wisconsin Technology Council (Tech Council). (Barba, 2006) The Tech Council 
was created in 2001 as an independent, non-profit science and technology advising institution to 
the Governor and the Legislature of Wisconsin. It has members from various levels of education, 
research institutions, technology companies, venture capital firms, government representatives. 
(Wisconsin Technology Council, 2009)  
In November 2005 Governor Doyle vetoed the bill prohibiting therapeutic and reproduc-
tive cloning. His reasoning was related to the fact that Wisconsin has a leading role in stem cells 
research. In a speech the governor said: 
 “the bill would criminalize some of the most promising scientific tech-
niques used by stem cell researchers, not only potentially delaying cures 
to some of humanity’s oldest and deadliest diseases but also costing Wis-
consin jobs in the future.” (Doyle, 2005)
 The Wisconsin Life Science Initiative was created in response to the California Initiative 
because UW is considered to be the birthplace of stem cell research since it is the first place 
where hESCs were isolated. Governor Jim Doyle emphasized that this state initiative will build 
on the state money, “nearly $1 billion”(Ertelt, 2004), that was spent over the last decade on 
medical research facilities. He also said that:   
 "Other states, like California, are trying to play catch-up and build from 
scratch what we already have… Wisconsin can't match California dollar for 
dollar, but California can't match what Wisconsin already has, including the 
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best scientists in the world and first-class research institutions" (Ertelt, 
2004)
UW Madison is primarily funded by WARF, which also holds patents for many stem cell lines 
discovered at the University. It also hosts the WiCell Research Institute, which is a private, non-
profit supporting organization to the UW using private and federal funding to invest into stem 
cell research. These conditions make Wisconsin the most appropriate location for establishment 
of a stem cell bank that will be able to store and distribute stem cell lines to researchers. In 2005 
the first National Stem Cell Bank (NSCB) is created at the WiCell Institute by NIH. The six ap-
proved providers of stem cell lines (in the US: WiCell at UW-Madison, University of California 
-- San Francisco, and Novocell; international: ES Cell International in Singapore; Technion in 
Israel; and Cellartis in Sweden ) are allowed to deposit only the 21 stem cell lines included in the 
NIH hESC Registry. 
All stem cell lines have to pass a complete quality control process before distributing them 
to scientists. The testing process begins upon receipt of a new cell line and its purpose is to ver-
ify the line's identity, characteristics and purity (lack of contaminants). Currently only 16 cell 
lines have completed the quality control and are available for research. (Kelly, 2009)
Connecticut
Connecticut also approved state funding for stem cells research in January 2005. Governor 
Jody Rell decided to provide funds from the state's budget surplus of $315 million (in 2005). In a 
speech Governor Rell said:
“This fund is a catalyst, intended to attract other investments and generate 
opportunities for growth… It makes obvious sense from an economic 
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standpoint as well as a medical and scientific view. The growth of the bio-
science industry in Connecticut has been critical to our state’s economy, 
with pharmaceutical and biotech companies employing some 18,000 people. 
We intend to build on that leadership role.” (Rell, 2005)
 Her initial proposal was for $20 million over 2 years, but Yale School of Medicine Dean Robert 
Alpern, MD, suggested that long-term commitment for research funding is required in order to 
keep the state of Connecticut competitive among the states which already have legislature 
passed. (Przymusinski, 2005) A scientific breakthrough was a turning point in the governor's de-
cision to sign the legislation, which provides $ 100 million for human embryonic stem cell re-
search over 10 years. (Silverman, 2005)
In March 2005 the University of Connecticut (UConn) at Storrs announced their successful 
creation of embryonic stem cells from cloned cattle embryos. The Chinese scientist Xiangzhong 
“Jerry”  Yang that UConn was collaborating with was invited to lead the research activities at the 
National Center for Stem Cell Research in Beijing. He was determined to leave Connecticut if no 
state funding was provided for the research at UConn. (Hathaway, 2005)
The Stem Cell Research Advisory Committee was created as a control institution responsi-
ble for approving specific guidelines for scientists applying for grants, and it also overlooks the 
funds that are spent. According to their schedule the grants have been awarded starting in Sep-
tember 2006. State funding was allowed not only for research but also for facility construction 
activities. In order to comply with the Bush Administration requirements, federal funds have to 
be spent solely for stem cell lines included in the NIH Registry. This means that any stem cell 
research not related to those lines needs newly created facilities in order to be conducted. 
(Hathaway, 2006)
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Illinois
Illinois Governor Rod R. Blagojevich and Comptroller (financial supervisor) Dan Haynes 
announced in July 2005 that the state will provide financial support the to stem cell research ac-
tivities, which makes Illinois the first state in the Midwest to commit public money for stem cell 
research. In a speech Governor Blagojevich said:
“Since the federal government has chosen to stall the medical advancements 
that will come with stem cell research, it is up to the states to take action… 
We cannot allow our citizens to suffer when relief may be available… Stem 
cell research is a largely untapped medical resource that may lead to cures 
for painful diseases ranging from cancer to Parkinson’s. We owe it to people 
who are suffering to exhaust every possibility to better treat or perhaps even 
cure disease.”
On the other hand, comptroller Hynes said:
“Today, the state of Illinois made a down-payment on hope for the millions 
of Illinoisans or their family members who are suffering from devastating 
diseases or injuries. This is not hope clung tenuously to wishful thinking, 
but realistic hope, grounded in scientific advancements already made and 
strong consensus within the scientific community that stem cell research 
holds limitless potential… ”  (Blagojevich, 2005)
"In the world of medical research, the fight for cures is waged one grant at a 
time.  Today, I am proud to say we’ve given our scientists ten million more 
weapons to win that fight. In so doing, we are also giving hope to the mil-
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lions of Americans who suffer from debilitating diseases that stem cell re-
search has the potential to defeat." (Illinois Regenerative Medicine Institute, 
2006)
 The governor signed an executive order authorizing $10 million in grants for adult, cord 
blood and embryonic stem cell research. The money was directed to the Illinois Department of 
Public Health (IDPH) to create a program to award grants for development of treatment and 
cures involving stem cells. The initiative created the Illinois Regenerative Medicine Institute 
(IRMI). The IRMI program is responsible for issuing grants, and to establish appropriate re-
quirements and regulations complying with the Executive Order of Governor Blagojevich. It 
states that research involving human cloning is unlawful and no funding will be provided. The 
same rule applies for trading with embryonic or fetal tissue for research purposes. IRMI also has 
to set up time limits concerning extraction of embryonic stem cells from blastocysts. 
An independent review board was created by IDPH. It consists of eight members -- two 
experts in bioethics and six medical professionals from Ireland and from the US excluding Illi-
nois. The purpose of this panel is to overlook the grant award process and make an independent 
review of the grant applications.
Maryland 
Maryland had one unsuccessful attempt to provide state funding for human embryonic 
stem cell research. A bill stating that $23 million per year will be provided, including therapeutic 
cloning was approved in March 2005 by the Maryland House. Unfortunately, the same bill was 
vetoed in April 2005 on the last day of the Senate legislative session. (Nitkin, 2005) Governor 
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Robert L. Ehrlich made another attempt by proposing $20 million state funding in January 2006. 
(Wagner, 2006)
In March 2006, a bill approving $15 million over a year passed and Governor Ehrlich 
signed the legislation in April 2006. (Skalka, 2006) This initiative is also called the Maryland 
Stem Cell Research Act of 2006. During the legislative session in 2006 was established the 
Maryland Stem Cell Research Commission as an independent unit within the Maryland Technol-
ogy Development Corporation (TEDCO).  It was created to develop certain criteria and require-
ments for stem cell funding that will comply with the Maryland Stem Cell Research Act of 2006. 
The Commission set up the Maryland Stem Cell Research Fund (MSCRF), which is re-
sponsible for promoting state-funded stem cell research through grants given to public and pri-
vate institutions or researchers. The goals of MSCRF are to advance stem cell research and po-
tentially develop clinical applications and treatments for many diseases.  
The state budget earmarked $23 million for FY 2008 for the Maryland Stem Cell Research 
Commission that will be allocated to stem cell grants. (Medical News Today, 2008) Up to date 
more than $36 million was spent on financing 82 grants for stem cells research in the first two 
years of the Maryland initiative. For FY 2009, $18 million is allocated, which is the third year of 
state funding for stem cell research. (Maryland Stem Cell Research Fund, 2009)
New York
New York is one of the last states to approve state funding for stem cells research. Prior to 
the New York initiative, the state is third in the country in venture capital and NIH funding. It 
also has 32 academic biomedical institutions, 100 teaching hospitals and very well developed 
biotechnology and pharmaceutical industry. Considering that many states already allocated large 
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amounts of money particularly for stem cells research, a failure to act in time would risk the 
leadership that the state already has in this research area. (Barba, 2006)
In 2007 the State of New York passed legislation under the leadership of Lieutenant Gov-
ernor David Paterson. The initiative is decided to be $600 million over 11 years. The first state 
funding of $100 million was earmarked for FY 2007-2008. The remaining $500 million is allo-
cated for 10 years ($ 50 million per year). (Patterson 2008)
The 2007-2008 State Budget created the Empire State Stem Cell Trust and the Empire State 
Stem Cell Board. The Board's role is to provide grants for research that is related to the devel-
opment of stem cell biology and medicine. The Empire State Stem Cell Board consists of two 
committees: The Funding Committee (13 members) and Ethics Committee (13 members). The 
Funding committee has to make awards based upon the recommendations of an independent sci-
entific review, whereas the Ethics Committee has to make recommendations concerning scien-
tific, medical, and ethical standards. The first round of grants totaling $14.5 million is awarded at 
the beginning of 2008. (Patterson, 2008) According to the Board, human reproductive cloning is 
not allowed and no grants will be provided. 
The Institutional Development Grants are intended to increase the capacity of New York institu-
tions and establish the appropriate conditions for stem cells research to ensure efficiency and 
quality of the research. Another track of funding is focused on encouraging investigator-related 
research and Innovative, Developmental or Exploratory Activities (IDEA) in Stem Cell Re-
search. There are also Consortia Planning Grants that are encouraging establishment of collabo-
ration between New York State stem cell institutions and out of the state researchers and compa-
nies. A specific grant is targeted to support the development of pluripotent stem cell derivation 
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and developing potential therapeutic applications.  All of these grants are summarized in Figure 
3.3 above.
48
Figure 3.3: Distribution of State Funds for New York
Chapter 4: Focus on Massachusetts
Massachusetts Life Science Center
The Massachusetts legislature created a quasi-public agency called the Massachusetts Life 
Sciences Center (MLSC) in June 2006. (Massachusetts Life Sciences Center, 2006) It was cre-
ated to support the life sciences in the Commonwealth by investigating potential areas for in-
vestment in public and private institutions that contribute to the research and development in the 
state.  As the state Life Science Initiative was signed off the MLSC was assigned a key role in 
controlling investments. By managing the $1 billion state funding the MLSC is targeting in 
strengthening state’s leadership in the life sciences field. The major means to achieve that goal is 
to collaborate industry with academia, and medical research centers. 
Massachusetts Life Science Initiative (MLSI)
Massachusetts is the last state to pass state initiative for Stem Cell research. On June 16, 
2008, Governor Deval Patrick signed the “Act Providing for the Investment in and Expansion of 
the Life Sciences Industry in the Commonwealth”. The legislation represents a 10-year plan to 
invest $1 billion in stem cell research. This package consists of $500 million of bond funding 
earmarked for the Massachusetts Life Sciences Investment Fund, $250 million for the research 
grants, and $250 million for state tax incentives. (McDermott Will & Emery, 2008)
Massachusetts Stem Cell Bank
49
The MLSC made investment of $8.2 million for building the Massachusetts Human Stem 
Cell Bank located at the University of Massachusetts Medical School (UMMS) campus in 
Shrewsbury, MA. The decision was made in October 2007 (Shelton, 2007) and it served as a 
kick-start for the state initiative. The facility is placed in the University of Massachusetts Medi-
cal School (UMMS) and it is intended to store any type of stem cell lines no matter if they have 
been derived before or after President George Bush’s stem cell ban. The building has separate 
labs for NIH funded stem cells, and for non-NIH cell lines. The equipment and functionality of 
the labs is identical. The only reason that the separation was required is based upon the fact that 
the Stem Cell Bank was founded during the Bush Administration when the federal funding for 
stem cell research was limited to lines derived before 2001. (Borowski, 2009) The intense re-
search using stem cells that is taking place at universities near UMMS will benefit from the Stem 
Cell bank because this is a way for scientists to obtain the stem cells of interest for a short period 
of time. The Bank will be accepting cell lines to be deposited from various worldwide locations. 
Currently, it provides well maintained hESC lines and induced pluripotent stem (iPS) cell lines. 
They are professionally cultured and shipped to the researcher. At this point this service is pro-
vided free of charge. The facility also has Education and Training division that has a goal to in-
volve K-12 programs and the community in technical training and education programs.
International Stem Cell Registry  
Another project that the MLSC funded with $570, 000 was the International Human Stem 
Cell Registry at UMMS. Its purpose is to create a database with all information that researcher 
might need concerning specific type of cell line. The registry was launched in September 2008 
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and it includes catalog of references to published and unpublished journals and research papers 
related to each hESC line. In one of his speeches Governor Patrick said:
“The International Stem Cell Registry will provide important information 
for stem cell research that will lead to cures for illnesses, a stronger econ-
omy and good jobs at good wages in every region of the Commonwealth.” 
(Shelton, 2008)
The database information is organized at different levels of difficulty depending upon the inter-
ests of the readers. For example, researchers can reference the website when writing research pa-
pers; whereas, patients could access the database in order to inform themselves. The benefit for 
doctors would be the opportunity to stay informed with the newly discovered therapies and ad-
vancements in medicine resulting from stem cells research. The Stem Cell Registry is constantly 
updated and will provide the latest information in this field. Currently, this database is the only 
one in the world.   
Universities
Massachusetts has great intellectual potential in that it houses some of the world’s most 
well-known universities. Higher education provides highly skilled people who create the 
workforce of the state industry. Universities generate a great deal of intellectual property though 
research and development programs. Currently, the State of Massachusetts has certain drawbacks 
in technology transfer, especially in commercialization of products and devices developed in 
those institutions.  This valuable asset that the state has needs to be utilized and turned into 
economic benefit. There is a study called the “Growing Talent Initiative”  that was initiated before 
the MLSI. Its purpose was to identify business needs and to work with government, higher 
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education, industry, and training organizations in order to establish collaboration between the 
aforementioned institutions. Studying industry needs and matching those needs with the 
academic development of the population starting from early stage education, such as K-12, and 
finishing with higher education, such as Bachelor’s, Master’s Degree and even PhD programs, is 
of great importance for the quality of the state workforce. Universities and academic medical 
centers are the teaching facilities that are responsible for providing a well-prepared workforce to 
enter the business market and become employees that will contribute to the general development 
of the life sciences. As a result these employees will be generating revenue for the companies 
that they work for and also their income will be generating state taxes and income taxes.
Grants
Half of the state initiative ($500 million) is earmarked for the Life Sciences Investment 
Fund. It is controlled by the MLSC and is planned particularly for research grants and loans. This 
investment is targeted primarily for higher education, training programs, and facilities 
construction. The funding will be provided to qualified life sciences projects or “certified life 
sciences companies.” 
Massachusetts is #1 in the national ranking list of NIH funding per capita. As shown in the 
figure below (Figure 4.1), the state has unquestionable leadership among 9 other states that are 
chosen by the highest number of biotechnology employees.    
In spite of the fact that federal funding is at such high levels, the funding is still insufficient 
for the amount of research that is being conducted in the state, especially when the NIH funding 
has been lower for the last 2 years. Because other states already have strong state initiatives from 
2004, the state of Massachusetts is required to take action in order to prevent educated people 
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from leaving the state. The state initiative grants are intended to compensate for the lowered NIH 
funding after 2006.
Small Company Investments
The State of Massachusetts has a strong educational and innovational advantage compared 
to other states. Combining those strengths with the long tradition of company clustering brings 
benefits for the organization and the community in which the clusters are located, and creates 
better opportunities for easy collaboration. The phenomenon of business clustering was defined 
by Michael Porter at the Harvard Business School. (Coleman, 2008) It is considered a business 
tool that helps geographically related companies that share the same area of interest to collabo-
rate and have the advantage of sharing infrastructure, equipment, and experts in order to advance 
the life sciences field. The Commonwealth’s life sciences Super Cluster includes various organi-
FIgure 4.1: Chart listing the top ten states in order of NIH funding totals and then showing funding per biotech em-
ployee
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zations and institutions that work together bonded by the inspiration for innovation. The best 
universities, medical schools, biotechnology companies, medical device companies, and pharma-
ceutical companies are involved in this Super Cluster. Also venture capital and trade councils are 
getting involved to support the collaboration. The cluster is located in the heart of the Boston 
area – the Boston-Cambridge region where the Harvard and MIT are located together with many 
companies that contribute to the newest technologies in the biotechnology field. It is of high im-
portance to the state and it has been growing over the past few years.
Another part of Massachusetts that has cluster seeds is the Worcester area. The main pur-
pose for establishing it in this region is the ability to encompass higher education institutions 
such as Worcester Polytechnic Institute (WPI), academic medicine institutions such as UMMS, 
and many life science companies that are directly involved in the life sciences and are willing to 
collaborate with other companies or institutions.     
The MLSC is working on number of programs to provide additional funding for the Clus-
ter and support the Small Businesses throughout their struggle with commercialization of prod-
ucts. Early-stage companies are eligible to apply for additional financial help through the Life 
Sciences Accelerator Program (Massachusetts Life Sciences Center, 2008) of the MLSC. This 
program is intended to support selected companies with their transferring of research and devel-
opment products into the market.  
Tax Incentives
The MLSI provides a tax incentive program. It does not exceed $25 million per year and 
the budget is managed by the MLSC. The incentive is effective from January 1st, 2009 to De-
cember 31st, 2018. (McDermott Will & Emery, 2008) Companies that are eligible to apply have 
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to be certified as life science companies from the MLSC board. They should be working to better 
the understanding of human physiology and medicine and its application in therapeutics. 
The certification process includes filing a Certification proposal that consists of projected 
revenue that the project will generate, estimated number of newly employed people, projected 
average salary for full-time employee, and plan for achieving that proposal. The companies have 
to consider both state revenue and commercial revenue. Another requirement is to have an 
agreement with a banking institution that would guarantee that part of the deposits will be 
allocated for loan payments. The company has to present any documentation justifying the 
project that they will be involved in. The following list highlights some of the tax incentive 
benefits for the certified companies:
• 10 percent Investment Tax Credit for qualifying property used exclusively within 
Massachusetts (refundable at 90 percent and may be carried over)
• Carryover of net operating losses for 15 years
• 100 percent credit for FDA User Fee 
• Elimination of the sales throwback provision
• Extension of research and development credit to certain activities performed outside of 
Massachusetts (refundable at 90 percent and may be carried over)
• Qualification as a “research and development”  corporation for purposes of the sales and 
use taxes
• Elimination of the sales tax for purchases made by certified life sciences companies for 
the development of their utility systems
• Deduction for qualified clinical testing expenses for orphan drugs
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• Credit against excise tax for clinical trial expenses conducted in and out of Massachusetts 
(McDermott Will & Emery, 2008)
The certification lasts for 5 years and the companies are required to submit annual report with the 
MLSC to track the progress of the initially set projected benefits.
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Chapter 5: Recommendations for Massachusetts
Summary
Following is a table (Table 5.1) which summarizes each area of investment that this 
report gives recommendations on. For the sake of brevity, the disadvantages of each category 
are not shown but will be discussed in later sections.
Recommendation 
Area
Returns Recommendation 
Level
Basic Research Patents and Knowledge Moderate
Universities Training, teaching, and research High
Small Pharma./ 
Start-up 
Companies
Taxes, Job Creation, and Product 
Development
High
Small Business 
Clusters
Cost Efficiency and Collaboration High
Large Pharma. Taxes and Job Creation Moderate
Collaborations Coordination of Industry and Education 
and Improved Employee Base
High
Transportaion Technology Transfer Low
Storage Support Research, Education, and Industry High
Infrastructure Facilitates Population Growth and Site 
Creation
Moderate
Tax Incentives Long-term Establishment of In-State 
Companies and Attraction of Out-of-State 
Companies
High
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Table 5.1: Summarization of Recommendations for MLSI
Basic Research
 As stated before, because there is as of yet no major marketable embryonic stem cell 
based products or therapies, basic science is still an area of research. In order for new therapies 
and products to be created, it is necessary that research is continued within the field so that a 
better understanding can be obtained. However, due to the fact that the broad materials and 
process patents, such as the Thomson patents held by WARF, and the time advantage that states 
such as California and Wisconsin have, basic science should be considered as a necessary but not 
highly recommended area of investment. Trying to invest in a new research company in 
Massachusetts will not be profitable because as seen with research company Geron in Table 2.1,  
embryonic stem cell research companies have yet to generate a positive revenue. This is largely 
in part that these companies have no marketable product to generate revenue, and instead rely 
heavily on collaborations with large business and investors in order to support the company’s 
research expenses.
Another drawback to basic research is that although material transfers for research 
purposes can be utilized for little to no cost, no marketable products can be developed from such 
research. Therefore, any understanding gained or breakthroughs found must remain in the 
educational sector. Any attempt at marketing further developments of broad base patents must be 
done through the original patent holder rather than by the new inventor. One way to get around 
this is if a product is developed from research utilizing the patented material but the product 
itself is not dependent on the material or process already patented. Overall, not much can be 
expected in terms of direct investment returns, however the further development of the 
technology is vital in order that the promise of stem cells actually be carried to fruition. This 
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technology is still very much in its infancy and so there are many avanues yet to be explored that 
go beyond the original broad patents.
Universities 
Universities and academic medical centers are the primary grant recipient in any of the 
State Stem Cell Initiatives. Because these institutions play an important role in stem cells 
research, they are used as teaching facilities to better train people to make them more suitable for 
future employment. Massachusetts has historic traditions in the higher educational success. One 
of the most common returns from investment in universities and medical schools is patents. 
Intellectual property has a high potential for economic benefit for the state not only because of 
the licensing fees, but also because of the possible commercialization of the patented products. 
The figure below (Figure 5.1) shows a comparison of patents issued per state and per 100,000 
people for the year of 2006, most of which provided funding for stem cells. MA has leading 
position in the list, which creates potential for future business creation if the state focuses its 
attention and sponsorship on technology transfer and manufacturing. By focusing on technology 
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Figure 5.1: Table showing patents issued by state and per 100,000 people
transfer, better communication, and collaboration between academia and business, the 
Commonwealth of Massachusetts would be able to generate large profits as long term returns on 
investments in grants and infrastructure. The Universities in Massachusetts already have an 
advantage in that they can receive stem cells and information about any stem cell line. The 
creation of the Stem Cell bank and the International Registry is of great convenience. 
As it was mentioned in the background research of the paper, Massachusetts is a national 
leader in NIH funding per capita. Another ranking was conducted so that only states that provide 
funding for stem cells were included in a comparison chart showing how much funding each 
state provides per capita based on the Employed Population only*.  The graph below (Figure 5.2) 
clearly shows that Massachusetts has the advantage in State Initiative Investment over its peers. 
Taking into account the aforementioned leadership position of Massachusetts in terms of funding 
per capita, it can be concluded that the state would be able to attract researchers and new faculty 
into the area due to the high levels of funding available. Another conclusion can be made about 
university grants. Given that the research grants are intended mostly for higher education 
institutions, the figure below (Figure 5.3) shows the ranking of Massachusetts with the rest of the 
states that have State Initiative for Stem Cells Funding. The calculation is based upon the number 
of people enrolled in College and Graduate School. The result of that comparison reveals that 
MA ranks second only to Wisconsin. Considering that data, it would be beneficial for 
Massachusetts to invest in higher education and to provide grants for research work that goes 
beyond basic research. This is the method to attract people willing to pursue higher education in 
the life sciences. The state will be much more capable to finance programs that will support 
college level students and develop further their skills by preparing them for either future research 
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* Employed population data were obtained from the US Census Bureau. For computation purposes only, Employed Civilian La-
bor Force data from 2000 Census were considered    
work or by creating the base of a highly educated workforce that would be beneficial for  both 
the industry and the Commonwealth.
Small Pharmaceutical and Start-up Companies
 Small pharmaceutical and small start-up companies are both highly recommended for 
investment because of the potential that they posses. Potential is the keyword to remember when 
investing because, as a whole, the majority of these small pharmaceuticals and start-up 
companies will fail and disappear. However, it is the small percentage which are able to succeed 
through whom the returns will be made. While large companies are able to create huge revenues, 
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Figure 5.2: Chart showing state initiative spending per capita
their production costs are also huge. On the other hand, a small start-up or pharmaceutical 
company is able to run and thrive on significantly less amounts of money. As a result, investing 
small portions into a number of small start-ups and pharmaceuticals is prudent. The small 
percentage that succeed will return back the initial investment in one of following two ways: 
either the company will seek out an exit strategy and sell itself to a larger pharmaceutical 
company and thus return a percentage of that money returns to the state, or in very rare 
circumstances, the company will grow into a large and thriving company giving the same returns 
as those of a large company but for significantly less cost. Therefore, it is highly recommended 
that a portion of the 1 billion dollars be invested into a number of small start-up and 
pharmaceutical companies. 
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Figure 5.3: Chart showing investment per capita enrolled in higher education
Small Business Clusters
 Small business clusters are another important area of investment because it gives an 
opportunity to small business to work together in order to expedite research by bringing 
specialties of different companies together. Small companies that are unable to afford the high 
end machines that may be necessary for research are provided for with the money invested into 
this category, and it allows a collaboration between the companies to work together to find new 
research and come up with products. This is a highly recommended investment it gives the 
opportunity of minds to work together in order to take research of the field into new stages of 
understanding.
Large Pharmaceuticals
 The appeal of investing into large companies is that if a new branch is set up it will result 
in a number of benefits for the economy of Massachusetts. Having a branch of a major company 
means that it is supported by a large money making corporation and also that the company will 
be able to make money soon after starting its operations. With money making operations starting 
so quickly, income taxes will be able to start returning the initial investment. For instance, if 
Baxter International were able to make a revenue of $11, 263 million*, then an income tax of 
9.5%† will create a return of approximately $1, 069 million to Massachusetts solely from the 
company’s income. Also, it will both stimulate and return investment in the form of employees. 
The creation of a new branch creates a number of new job opportunities, Baxter International has 
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* Total annual revenue for 2007.
† See Tax Incentive section.
20,600 employees in Illinois alone. (Baxter International Inc., 2009) With the new jobs come 
more income taxes and possible residential taxes if the new employees need to move into 
Massachusetts. Investment into these companies would be a long term investment, requiring the 
allocation of a certain amount of money periodically over a ten year period. However, this 
investment is something that is not recommended because large pharmaceutical companies make 
revenues that can dwarf the 1 billion dollars that Massachusetts is seeking to invest over ten 
years. Even a $1 billion investment is not enough to affect the larger companies, and thus should 
not be done. Instead if the benefits of creating a branch can be gained more prudently by 
investing in infrastructure to create locations condusive to the moving in of a large company. By 
using this in tandem with the tax incentive of the MLSI, companies are much more likely to set 
up branches within Massachusetts than with a direct investment.
Collaborations of academia and business
The development of Massachusetts into a leader in the life science field was cultivated by 
the highly educated population and the innovative workforce created from it. It is more compli-
cated to maintain that position as the global economy becomes more competitive, particularly in 
the stem cell field in lieu of the federal funding restrictions put in place by the Bush Administra-
tion. Other countries began to take on leading roles within the field and this spurred some states 
to provide funding to continue research in this most promising field – stem cells therapy. 
Massachusetts is taking action to regain its leading position by passing legislature for a $1 
billion investment over 10 years. One of the biggest challenges is to coordinate industry re-
quirements for workforce and educational centers, where the workforce is trained. The state of 
Massachusetts conducted a study, called Growing Talent, in the form of survey in order to deter-
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mine what the industry needs are and how to establish collaboration between academia and in-
dustry. In the long run, this attempt hopes to result in a better employment base.     
  Taking a look at the California strategy of collaboration between academia and industry it 
should be noticed that the state’s efforts are focused on public higher educational institutions. 
What is important in the example of California is that those collaborations were initiated before 
Proposition 71. The California Community College Biological Technologies Initiative is a state-
wide collaboration between biotechnology programs in the community colleges. (California 
Community College Biological Technologies Initiative, 2009) The California State University 
Program for Education and Research in Biotechnology (CSUPERB) was founded in 1987 to 
promote biotechnology in California. (UMass Donahue Institute, 2008) This organization serves 
as collaboration between the California State Universities and industry, state government and the 
public on issues related to biotechnology. (CSUPERB, 2009) The California Institute for Science 
and Innovation was created in 2000 as a result of collaboration between the state and industry. 
The institute is intended to “create a new environment for industry scientists to collaborate in 
fundamental research and to educate future scientists.” (California Institute for Science and In-
novation, 2008)
This strong relationship between academia, business and the state government is of great 
importance for Massachusetts as well. Having high intellectual and innovational potential, strong 
intellectual property, and various sources of funding for biotechnology gives the state high poten-
tial for financial impact on its economy. Maintaining those resources requires effective commu-
nication and collaboration between institutions. The Growing Talent study was initiated in order 
to determine what areas of the higher education have to be improved so that the workforce meets 
the industry needs. This was evaluated by conducting surveys and interviews of human resources 
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representatives of 100 Massachusetts-based institutions. The study included professionals from 
every sector of the life science industry, such as academic medical centers, biotechnology and 
pharmaceutical companies, medical device companies, clinical research organizations, venture 
capitalists, etc. (UMass Donahue Institute, 2008)
The following figure (Figure 5.4) shows the result of a survey about the difference between 
public and private school graduates according to employers. The common opinion is that 
employers consider that PhD and Master’s degree recipients are well prepared after graduation. 
In contrast, more efforts have to be made to improve Bachelor’s degree education. The action 
that the state has taken to support school-to-career development is the Internship Challenge 
program offered by the MLSC. 
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Figure 5.4: Chart showing opinion poll of preparedness of graduates of varied levels
Because Massachusetts relies heavily on international specialists for higher education 
positions, there is a high level of uncertainty as to the number of students that will stay in 
Massachusetts and generate benefits as employees. As a collaboration program the state has to 
increase the pipeline for residents of Massachusetts that enter higher education and also provide 
means for hiring more residents in the life sciences. (UMass Donahue Institute, 2008)
One of the new strategies suggested by the Growing Talent report is the improvement of 
technical trainings. Employers who identify an area where there is an insufficient supply of 
workers could partner with community colleges and send their employees for training programs 
in the life sciences. This is the case with Wyeth, which trained their workers at Middlesex 
Community College in the area of bio-manufacturing. (UMass Donahue Institute, 2008)
The figure (Figure 5.5) below makes comparison of the answers from the survey about em-
ployers’ opinions about workforce coming from private 4-year colleges, public 4-year colleges, 
2-year colleges, and corporate education programs. Survey respondents think that graduates from 
private 4-year colleges are better prepared than any other type of schooling. Their opinion is that 
MIT, Harvard University, Northeastern University, WPI and Boston University (UMass Donahue 
Institute, 2008) are the leaders within the life science education community. 
Collaboration is a highly recommended area of investment by the initiative because it will 
reduce costs by eliminating duplication and creating more life science clusters, and it will create 
more economic benefits by creating a workforce better suited to meet the needs of the industry. 
Transportation
 Transportation was an important consideration of stem cell research as it may be 
important to transfer the research of one branch to another. However upon further investigation 
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transportation is a tricky area of investment due to the number of state border crossing fees and 
the fact that there are a number of already established transportation companies that hold 
significant presence in the transportation industry. For material transfers on a smaller scale, the 
regular shipping agencies such as FedEx or UPS are able to accomodate. Their overnight 
delivery capabilities and hyper accurate package tracking allow for easy shipment of small 
frozen cell shipments anywhere in the domestic United States. For larger shipments, such as lab 
transfers, or overseas shipments, companies that specialize in transfering biological materials are 
needed. Smaller shipments that need to be preserved longer are easily handled with the 
packaging inovation of Minesotta Thermal Science or Cole-Parmer, which sell specially 
designed packaging for cryogenically preserved tissue.  Companies, such as Pacific Scientific 
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Figure 5.5: Chart showing opinion poll of preparedness of graduates for the life sciences
Transport on the west coast, have the shipping and storage capabilities and specialize in lab 
transfers and other large-scale transfers.
Storage
 Truly one of the few untouched areas, there exist only a few designated ES cell storage 
facilities in the world. Most stem cell banks, such as Cryo-cell International or CorCell, 
specialize in umbilical cord blood purification and UCSCs isolation to be set aside for when the 
donor may need it. Because of this specialization, these facilities fall under the jurisdiction of 
blood banks and so avoid the entire controversy of stem cell ethics. Prior to the grant given to set 
up the ES cell bank in Shrewsbury, MA, there were only two major ES cell repositories in the 
world. The first is the NSCB in the United States. However, since this facility recieves NIH 
funding, up until recently it only accepted stem cell lines permitted under the Bush 
administration. The other is the United Kingdom Stem Cell Bank which accepts all viable cell 
lines through an intensive screening process. Because there is so little activity in this field, the 
North American market is still very open. Also, stem cell banks are the only primarily stem cell 
based companies that end up making money by charging for the storage and retrieval of stem cell 
lines. Because Massachusetts wants to establish its stem cell bank with as many lines as possible 
and promote non-monetary returns such, as an open research environment and educational 
opportunities for all levels, the bank does not charge anything for lines being donated or lines 
being retrieved. The hope is that over the 10 years that the grant is in place, the Bank will 
become well established and be able to pay for itself once the initial investment runs dry.
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Infrastructure
 As stated before, in order to support the creation of new companies we first need to make 
sure that the infrastructure is able to support it. The first part of infrastructure is the expansion 
and updating of utilities and transportation flow. This might mean that sewage systems need 
expanding, highway roads expansion, parking lot creation, etc. Although this infrastructure does 
not bring profit in a short term, it is an essential part in the process of stem cell research in that it 
lays a good foundation for the ongoing growth in the state’s life science industry. The second part 
is the building or relevant technical structures that can offer support to develop new cures that 
better treat diseases, and facilitate the operation of stem cell research. For example, through the 
MLSI, one of the primary objectives is to create a stem cell bank and registry for the archiving 
and distribution of NIH approved and  non-NIH approved ES cell lines. The bank and registry 
will provide a great resource for both the region and the nation. Infrastructure is a necessary 
investment, but should only be seen as a necessity, and more of an indirect investment towards 
other more highly recommended areas of investment.
Tax Incentives
The economic benefits calculated in other states, such as California and New Jersey suggest 
that the state of Massachusetts is expected to generate state and income taxes from the newly 
created jobs throughout the 10-year Stem Cell Initiative.  Following that pattern, the short term 
return for the state will be generated by income taxes from the worker’s income and the residen-
tial taxes from housing. From the beginning of the initiative, the MLSC has committed $42.5 
million to support the life sciences. (Massachusetts Life Sciences Center, 2009) These invest-
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ments attracted more than $352 million in federal and private funding. The projected benefit is 
that more that 950 new jobs will be created across the state due to the initiative financing. 
So far, life science businesses in Massachsetts have taken active role in financing various 
programs. For example, the company RainDance Technologies moved its operations from 
Connecticut to Lexington, MA. Through the MLSC, it received a $250,000 annual grant for 3 
years  in partnership with the Harvard School of Engineering and Applied Sciences and Physics 
Dept. for development of a new fluorescent activated cell sorter. The relocation of the company 
will generate taxes for MA through it’s 60 employees. (Linked In, 2009)
The state would be able to expect many of the corporations to generate corporate income 
taxes in the long run. Since one of the weaknesses of MA is the high level of Corporate Taxes it 
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Figure 5.6: Chart showing corporate income taxes by state. Source: Governor Barbour, 2006
was necessary to create a State Tax Incentive for qualified life sciences companies. This is the 
method to support the small business and start-up companies in particular, and to attract big 
companies to locate facilities or expand in Massachusetts. In the figure (Figure 5.6) above is 
provided comparison of the corporate income taxes in most states that provides federal funding 
for stem cells research. 
The high corporate income tax of Massachusetts is a disadvantage that makes the state 
unattractive for companies even though there are other valuable resources, such as highly 
educated people, the MLSI, etc. Therefore, tax incentives are highly recommended in order to 
counterbalance the negative stipulation acrewed since the early 1980s.
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Conclusions
In general, the decisions of the MLSC have reflected the recommendations provided 
above. Initial funding was given to infrastructure to provide for companies moving into 
Massachusetts and to set up facilities such as the Massachusetts Human Stem Cell Bank and 
the International Stem Cell registry. Tax Incentives were also put in place for qualifying com-
panies in order to support growing companies and bring in larger companies from outside of 
the state. Basic research and academia have been supported through grants. Training has been 
offered through UMMS via the Massachusetts Human Stem Cell Bank at both the industry 
and university level. Massachusetts has even sought to build a foundation for the next genera-
tion of life science employees by providing elementary through secondary level programs to 
interest youth in the life sciences. The decisions that Massachusetts is now making are well-
suited for long-term economic and educational gains.
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Appendix A: List of Grants by State
Illinois
A complete list of researchers and institutions receiving grants is provided below: 
• “$870,000 - Guillermo A. Ameer, Northwestern University for stem 
cell-based vascular tissue engineering to enable the development of 
replacement blood vessels and therefore eliminating the need to harvest 
existing blood vessels from the patient.
• $800,000 - George H. DeVries, University of Illinois at Chicago for stem 
cell therapy for recovery from ischemic stroke.
• $1,999,944 - Mary J. Hendrix, Children’s Memorial Hospital for reversal 
of disease progression by stem cells.
• $1,990,309 - Ronald Hoffman, University of Illinois at Chicago for the 
Center for the Development of Stem Cell Therapies for Human Diseases to 
focus on the use of human embryonic stems cells and adult tissue-specific 
stem cells for the treatment of blood disorders, lung diseases and heart 
repair.
• $800,000 - Gwendolyn L. Kartje, Hines VA Hospital for human adult bone 
marrow-derived stem cell therapy for recovery from Ischemic stroke.
• $250,000 - Stephen J. Kaufman, University of Illinois at 
Urbana/Champaign for therapeutic implementation of mesoangioblast stem 
cells in muscular dystrophy to advance stem cell therapy for muscle and 
neurodegenerative disease and injury and provide a mechanism for 
repairing a variety of diseased tissues.
A1
• $473,212 - Dorothy A. Sipkins, University of Chicago for mechanisms of 
hematopietic stem cell homing in normal and disease states with the goal of 
understanding the molecular signals that blood-producing cells use to travel 
to specific areas where these cells can survive and regenerate.
• $1,400,000 - Patrick J. Stiff, Loyola University for unlocking the clinical 
potential of umbilical cord blood derived stem cells to use as both blood 
cells as well as other tissues, including the heart muscle and nerves.
• $564,512 - Xiaozhong A. Wang, Northwestern University for genetic 
control of pluripotency and differentiation in embryonic stem cells to 
control the self-renewal and multipotency of stem cells.
• $591,322 - Matthew B. Wheeler, University of Illinois at 
Urbana/Champaign for mesenchymal stem cells using high-speed robot to 
culture, screen and differentiate stem cells as well as assess the suitability as 
an alternative to bone marrow as a source of adult stem cells in tissue 
engineered devises for the clinical reconstruction of bone and soft tissue 
defects using human-patient derived fat.” (Blagojevich, 2005)
California
“The Independent Citizens Oversight Committee approved Comprehensive Research 
Grants to the following researchers (Note: the dollar amounts shown are the four-year budg-
ets requested by each applicant and are subject to review and revision by CIRM, prior to 
the issuance of grant awards):
A2
Applica-
tion #
Principal Investiga-
tor
Institution Title Amount
RC1-
00100-1 
Baker, Dr. Julie C Stanford University Functional Genomic Analysis of 
Chemically Defined Human Embry-
onic Stem Cells
$2,628,635
RC1-
00104-1
Bernstein, Dr. Harold 
S
University of California, 
San Francisco
Modeling Myocardial Therapy with 
Human Embryonic Stem Cells
$2,229,140
RC1-
00108-1
Crooks, Dr. Gay Miriam Children's Hospi-
tal of Los Angeles 
Regulated Expansion of Lympho-
hematopoietic Stem and Progenitor 
Cells from Human Embryonic Stem 
Cells (hESC) 
$2,551,088
RC1-
00110-1
Donovan, Professor 
Peter
University of California, 
Irvine
Improved hES Cell Growth and Dif-
ferentiation
$2,509,438
RC1-
00111-1
 Fan, Dr. Guoping University of California, 
Los Angeles
Epigenetic gene regulation during 
the differentiation of human embry-
onic stem cells: Impact on neural 
repair  
$2,516,613
RC1-
00113-1
Fisher, Dr. Susan J. University of California, 
San Francisco
Constructing a fate map of the hu-
man embryo
$2,532,388
RC1-
00115-1
Gage, Professor Fred 
H. 
The Salk Institute for 
Biological Studies
Molecular and Cellular Transitions 
from ES Cells to Mature Function-
ing Human Neurons 
$2,879,210
RC1-
00116-1
Goldstein, Professor 
Lawrence S. B. 
University of California, 
San Diego 
USING HUMAN EMBRYONIC 
STEM CELLS  TO UNDERSTAND 
AND TO DEVELOP NEW 
THERAPIES FOR ALZHEIMER'S 
DISEASE
$2,512,664
RC1-
00119-1
Heller, Professor Ste-
fan
Stanford University Generation of inner ear sensory cells 
from human ES cells toward a cure 
for deafness 
$2,469,373
RC1-
00123-1
Lee, Dr. Jang-Won CHA Regenerative Medi-
cine Institute 
Establishment Of Stem Cell Lines 
From Somatic Cell Nuclear 
Transfer-Embryos in Humans 
$2,556,066
RC1-
00124-1
Lee, Dr. Randall 
James
University of California, 
San Francisco
Embryonic Stem Cell-Derived 
Therapies Targeting Cardiac 
Ischemic Disease 
$2,524,617
RC1-
00125-1
Lipton, Dr. Stuart  A. Burnham Institute for 
Medical Research
MEF2C-Directed Neurogenesis 
From Human Embryonic Stem Cells 
$3,035,996
RC1-
00131-1
Marsala, Dr. Martin University of California, 
San Diego 
Spinal ischemic paraplegia: modula-
tion by human embryonic stem cell 
implant. 
$2,445,716
RC1-
00132-1
Mercola, Dr. Mark Burnham Institute for 
Medical Research
Chemical Genetic Approach to Pro-
duction of hESC-derived Cardio-
myocytes
$3,036,002
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RC1-
00133-1
Nusse, Dr. Roel Stanford University Guiding the developmental program 
of human embryonic stem cells by 
isolated Wnt factors
$2,354,820
RC1-
00134-1
Palmer, Professor 
Theo D 
Stanford University Immunology of neural stem cell fate 
and function 
$2,501,125
RC1-
00135-1
Pleasure, Dr. Samuel 
J.
University of California, 
San Francisco
Human stem cell derived oligoden-
drocytes for treatment of stroke and 
MS 
$2,566,701
RC1-
00137-1
Reijo Pera, Dr. Renee 
A.
University of California, 
San Francisco
Human oocyte development for ge-
netic, pharmacological and repro-
gramming applications
$2,469,104
RC1-
00142-1
Srivastava, Dr. Dee-
pak
The J. David Gladstone 
Institutes
microRNA Regulation of Cardio-
myocyte Differentiation from Hu-
man Embryonic Stem Cells
$3,164,000
RC1-
00144-1
Tarantal, Professor 
Alice F.
University of California, 
Davis 
Preclinical Model for Labeling, 
Transplant, and In Vivo Imaging of 
Differentiated Human Embryonic 
Stem Cells 
$2,257,040
RC1-
00148-1
Xu, Yang University of California, 
San Diego 
Mechanisms to maintain the self-
renewal and genetic stability of hu-
man embryonic stem cells
$2,570,000
RC1-
00149-1
Zack, Dr. Jerome A University of California, 
Los Angeles
Human Embryonic Stem Cell 
Therapeutic Strategies to Target HIV 
Disease
$2,516,831
RC1-
00151-1
Zarins, Dr. Christo-
pher K. 
Stanford University Engineering a Cardiovascular Tissue 
Graft from Human Embryonic Stem 
Cells
$2,618,704
RC1-
00345-1
Keirstead, Dr. Hans 
S.
University of California, 
Irvine 
hESC-Derived Motor Neurons For 
the Treatment of Cervical Spinal 
Cord Injury 
$2,396,932
RC1-
00346-1
Kriegstein, Dr. Ar-
nold R.
University of California, 
San Francisco
Derivation of Inhibitory Nerve Cells 
from Human Embryonic Stem Cells 
$2,507,223
RC1-
00347-1
Leavitt, Dr. Andrew 
D.
University of California, 
San Francisco
Understanding hESC-based Hema-
topoiesis for Therapeutic Benefit 
$2,566,702
RC1-
00353-1
Wallace, Professor 
Douglas C.
University of California, 
Irvine 
The Dangers of Mitochondrial DNA 
Heteroplasmy in Stem Cells Created 
by Therapeutic Cloning
$2,530,000
RC1-
00354-1
Weissman, Dr. Irving 
L
Stanford University Prospective isolation of hESC-
derived hematopoietic and cardio-
myocyte stem cells
$2,636,900
RC1-
00359-1
Zern, Professor Mark 
Allen
University of California, 
Davis 
An in vitro and in vivo comparison 
among three different human 
$2,504,614
(Carlson, 2007)
New Jersey
A4
The Commission on Science and Technology received 71 complete applications for New 
Jersey’s $5 million Stem Cell Research Grant program, including proposals from private life sci-
ence companies as well as New Jersey’s research universities and nonprofit institutions. 
The Commission voted Dec. 16 in a public meeting to award Stem Cell Research Grants to 
the following:
•Treena Arinzeh Ph.D. New Jersey Institute of Technology $295,362
Nanofiber Scaffold for Stem Cell Based Cartilage Repair
To test whether stem cells can be used to repair cartilage defects with the 
potential for providing new tissue engineering therapies that could help can-
cer patients who have had tumors removed from bones, osteoporosis and 
other cartilage and tendon damage.
•Rick Cohen Ph.D Rutgers University $299,403
Center for Applied Training in Human Embryonic Stem Cell Biology
To provide basic and advanced training in the field of human embryonic 
stem cell biology and to develop a well-trained pool of scientists in New 
Jersey proficient in hESC culture techniques with the goal of advancing 
New Jersey’s leadership in stem cell research.
•Ronald Hart Ph.D. Rutgers University  $275,590
Regulation of microRNA Gene Expression in Differentiating Neural Stem 
Cells
To understand and control differentiation of neural stem cells with the po-
A5
tential to produce specific cell types for therapeutic transplant in brain 
trauma, stroke, spinal cord injury, Parkinson’s and Alzheimer’s disease.
•Hristo Houbaviy Ph.D.  UMDNJ-RWJMS  $300,000
MicroRNAs MiR-290-295 in Blastocyst-Derived Stem Cells and the Early 
Mouse Embryo
To understand stem cell development and lineage determination with the 
goal of expanding and improving knowledge of areas of stem cell biology 
currently not well understood.
•Ihor Lemischka Ph.D Princeton University  $300,000
Genome-Wide Functional Analysis of ES Cell fate Regulation
To understand human embryonic stem cell decisions such as survival/death, 
renewal/determination and to understand how to maintain or induce specific 
cell fate with the goal of applying this knowledge to patient therapies.
•Randall McKinnon Ph.D. UMDNJ-RWJMS  $300,000
Gliogenic Potential of Human Placental Stem Cells
To identify mechanisms of glial cell generation from human placental cells 
with the goal of identifying a potential alternative to embryonic stem cells 
for clinical trials. In collaboration with Celgene, a New Jersey-based biotech 
firm ranked sixth largest internationally.
•Kateri Moore DVM  Princeton University  $299,970
Interactive Mechanisms of Stem Cells and Microenvironments
To further understand the mechanisms of stem cell self-renewal and com-
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mitment toward the purpose of developing new therapies or advancing ex-
isting therapies for use in drug development and for gene and cell therapy 
for immunological and other diseases.
•Richard Nowakowski Ph.D.  UMDNJ-RWJMS  $300,000
Molecular Circuitry of “Stemness” in the Developing CNS
To learn how to reprogram or teach transplanted cells how to generate the 
right type and number of necessary cells for cell-replacement therapies with 
the potential for replacing specific brain areas damaged by disease or injury.
•Robert Preti Ph.D. Amorcyte, Inc. $298,200
Bone Marrow Derived CD34 Cells for Treatment of Acute Myocardial In-
farction
To produce a cell therapy product using bone marrow-derived cells for 
treatment of coronary damage following a heart attack and advance the 
company’s federal Food and Drug Administration-approved clinical trials 
with the potential for new and more effective therapy for cardiac patients.
•Ling Qin Ph.D. UMDNJ-RWJMS  $300,000
PTH-Mediated AGFR Signaling in Stromal Stem Cell Growth and Multidif-
ferentiation
To conduct fundamental research using bone marrow stem cells with the 
potential to develop more effective treatments for low bone mass and simi-
lar disorders.
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•Monica Roth Ph.D. UMDNJ-RWJMS  $300,000
Selective Gene Delivery to Human Hematopoietic Stem Cells
To apply novel genetic screening approaches to stem cells with the potential 
of enhancing the ability to use stem cells and gene therapy in many clinical 
settings, including treating hematopoietic disorders and cancer.
•Junichi Sadoshima M.D. Ph.D.  UMDNJ-New Jersey Medical School 
 $300,000
Mechanisms of Mesenchymal Stem Cell Differentiation
To increase the efficiency of stem cell differentiation into cardiac myocytes 
by manipulating a particular signaling mechanism with the potential for de-
veloping an effective method to repair damaged heart tissues.
•Biagio Saitta Ph.D.  The Coriell Institute for Medical Research  $300,000
Role of Extracellular Matrix in Cord Blood Stem Cell Response to Cardiac 
Injury
To use stem cells derived from umbilical cord blood to study the molecular 
mechanisms of stem cells in repairing damaged areas of the heart with the 
potential to heal damaged tissue and preserve or regain function, offering an 
alternative to transplants which are possible but limited by the number of 
donors.
•Michael Shen Ph.D  UMDNJ-RWJMS  $300,000
Role of the Nodal signaling pathway in regulation of embryonic pluripo-
tency
A8
To enhance fundamental understanding of basic molecular functions in mice 
and human stem cells with the potential for improving manipulation of ES 
cells in culture for use in stem cell-based therapies including possible in-
sights into the genesis and dysregulation of cancer stem cells.
•Thomas Shenk Ph.D.   Princeton University  $300,000
Isolation and Characterization of Life-Extended Human Cord Blood Cells
To produce populations of stem cells from human cord blood that can be 
used to study the molecular characteristics of such cells including how to 
modulate these growth responses in vivo and in culture with the potential to 
improve the clinical uses of stem cells.
•Yufang Shi, DVM, Ph.D. UMDNJ-RWJMS  $300,000
Immunobiology of Mesenchymal Stem Cells
To investigate the mechanisms underlying stem cell mediated immune toler-
ance and its use in treatment of autoimmune disorders with the potential to 
lead to new treatment for many human diseases in which the immune sys-
tem attacks the body, including MS and asthma.
•Jay Tischfield Ph.D Rutgers University  $300,000
Genetic and Structural Analysis of Mouse ES Cells and their Derivatives
To study cultured ESC and confirm, monitor and regulate phenomena that 
would be deleterious to tissues derived from stems cells with the potential to 
prevent problems that could slow development of stem cell therapies. 
(New Jersey Commission on Science & Technology website, 2008)
A9
Massachusetts
Earmarked Funding:
•$12.9 million for facilities in Framingham
•$12.6 million for the I-93 interchange in Andover, Wilmington and Tewksbury
•$6.5 million for the William Stanley Business Park
•$10 million for a new nano and biomanufacturing facility at UMass Lowell
•$5.5 million for the Pioneer Valley Life Sciences Institute
•$1.1 million for three mobile labs in conjunction with Massachusetts Academy 
for Life Sciences
•$9.5 million for Tufts University
•$10 million for the Marine Biological Laboratory in Woods Hole
•$5 million for a regional incubation center in New Bedford in conjunction with 
UMass Dartmouth and Bristol Community College
•$5 million for a life sciences center at the Paul A. Dever State School in Taunton
•$10 million for the MA Small Business Matching Grant Fund
•$5 million for the MA Life Sciences Education Fund
•$90 million to UMass Worcester
•$95 million to UMass Amherst
•$10 million to UMass Boston in collaboration with the Dana-Farber Harvard Cancer 
Center
•$11.4 million to UMass Dartmouth
(McDermott Will & Emery, 2008)
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New York
A11
Appendix B: State Restrictions for Stem Cell Research and Use
Below is a table listing all of the states that have passed legislature in regards to research 
or use of stem cells. States not included have taken no official stance through legislature but 
may have implicit restrictions in place through political policies.
State/Jurisdiction
Statute Section
Specifically
permits research on 
fetus/embryo
Restricts research on 
aborted fetus/ embryo
Consent provisions to 
conduct research on 
fetus/embryo3
Restricts research on fetus 
or embryo resulting from 
sources other than abor-
tion
Restrictions of 
purchase/sale hu-
man tissue for re-
search
Arizona
§§36-2302, 2303 No
Yes, prohibits research on 
aborted living/non-living 
embryo or fetus
No
Yes, prohibits the use of 
public monies for cloning 
for research
No
Arkansas
§§20-17-802, 20-16-
1001 to 1004
No Yes, prohibits research on aborted live fetus
Yes, consent to con-
duct research on 
aborted fetus born 
dead
Yes, prohibits research on 
cloned embryos
Yes, prohibits sale of 
fetus/fetal tissue
California Health & 
Safety 2004 Proposi-
tion 71 §§ 123440, 
24185, 12115-7, 
125300-320
Yes, permits research 
on adult and embry-
onic stem cells from 
any source
Yes, prohibits research on 
aborted live fetus
Yes, consent to donate 
IVF embryo to re-
search
Prohibits sale of embryos 
and oocytes; prohibits pay-
ment in excess of the 
amount of reimbursement of 
expenses to be made to any 
research subject to
encourage her to produce 
human oocytes for the pur-
poses of medical research
Yes, prohibits sale 
for the purpose of 
reproductive cloning 
or for stem cell re-
search 
Connecticut §§4-28e; 
19a-32d et seq.
Yes, on embryos be-
fore gastrulation (a 
process during embry-
onic development)
 No
Yes, consent to donate 
IVF embryo to re-
search
 No
Yes, prohibits pay-
ment for embryos, 
embryonic stem cells 
unfertilized eggs or 
sperm donated fol-
lowing IVF treat-
ment 
Florida
§390.0111 No
Yes, prohibits on aborted 
live fetus No No No
Illinois
720 ILCS 510/6, 
510/12.1
Executive Order 6 
(2005);410 ILCS 110/
1 et seq.
Yes, permits research 
on embryonic stem 
cells, embryonic germ 
cells and adult stem 
cells from any source
Yes, prohibits on aborted 
living/
nonliving fetus
Yes, written consent to 
perform research on 
cells or tissues from a 
dead fetus other than 
from an abortion
Yes, prohibits research on 
fetus/fertilized embryo; 
prohibits funding under 
E.O. 6 (2005) of research on 
fetuses from induced abor-
tions and the creation 
of embryos through the 
combination of gametes 
solely for the purpose of 
research
Yes, prohibits sale of 
fetus/fetal tissue; 
prohibits purchase or 
sale of embryonic or 
fetal cadaveric tissue 
for research but 
permits reimburse-
ment for removal, 
storage and transpor-
tation for research
Indiana
§35-46-5-1, 
16-18-2-5.5
Yes, permits fetal stem 
cell research on pla-
centa, cord blood, 
amniotic fluid or fetal 
tissue 
Yes, prohibits research on 
aborted living/non-living 
embryo or fetus
Yes, consent required 
for fetal stem cell 
research
Yes, prohibits research on 
cloned embryos
Yes, prohibits sale of 
human ovum, zy-
gote, embryo or fetus
Iowa
§§707C.4
Yes, ensures that Iowa 
patients have access to 
stem cell therapies and 
cures and Iowa re-
searchers may conduct 
stem cell research
No No No
Yes, prohibits trans-
fer or receipt of the 
product of human 
reproductive cloning
Kentucky
§436.026 No No No No
Yes, prohibits sale of 
fetus/fetal tissue
A12
Louisiana
§14: 87.2 No No No
Yes, prohibits research 
on fetus/embryo in utero, in 
vitro fertilized embryo
No
Maine
22§1593 No No No
Yes, prohibits research on 
fetus/embryo born or ex-
tracted alive, only applies to 
in vitro fertilized embryos 
post-implantation
Yes, prohibits sale of 
fetus/fetal tissue
Maryland
83A§5-2B-01 et seq.
Yes, permits research 
on adult and embry-
onic stem cells
 No
Yes, written consent to 
donate unused 
IVF material to re-
search
Yes, prohibits donation of 
unused oocytes for state 
funded stem cell research; 
cloning of an organism 
beyond the embryonic stage 
is prohibited
Yes, prohibits valu-
able consideration 
for the donation or 
production of IVF 
material 
Massachusetts
112§12J, 2005 SB 
2039
Yes, on embryos that 
have not experienced 
more than 14 days of 
development (not 
including days frozen)
Yes, prohibits research on 
embryo/live fetus
Yes, written consent to 
perform research on a 
dead fetus and in-
formed consent to 
donate egg, sperm, or 
unused preimplanta-
tion embryos created 
for IVF
Yes, prohibits research 
on live embryo or fetus; 
also prohibits creation of 
fertilized embryo solely for 
research
Yes, prohibits sale of 
neonate, embryo or 
fetus for illegal pur-
poses; prohibits sale 
of embryos, gametes 
or cadaveric tissue 
for research
Michigan
§§333.2687-2688, 
§§333.16274-16275, 
333.20197, 
333.26401-26403, 
750.430a
No Yes, live embryo/fetus
Yes, written consent of 
mother to donate dead 
embryo, fetus or neo-
nate to research
Yes, prohibits research on a 
live
embryo or fetus, cloned 
embryo
No
Minnesota
§§145.421, 422 No No No
Yes, prohibits research on a 
live embryo or fetus up to 
265 days post fertilization 
Yes, permits the sale/
purchase of cell 
culture lines from 
nonliving human 
conceptus
Missouri
§§188.036, 037 No
Yes, prohibits research on 
a fetus alive pre-abortion No No
Yes, prohibits receipt 
of valuable consid-
eration for aborted 
fetal organs or tissue
Montana
§50-20-108(3) No
Yes, prohibits research on 
a live fetus No No No
Nebraska
§§28-342, 346, 71-
7606
No
Yes, prohibits research on 
aborted live fetus or the 
use of state funds for 
research on fetal tissue 
obtained from an abor-
tion
No
Yes, limits the use of state 
funds for embryonic stem 
cell research; restrictions 
only apply to state health-
care cash funds provided 
by tobacco settlement dol-
lars
Yes, prohibits sale, 
distribution or dona-
tion of viable aborted 
child
New Hampshire
§§168-B:1, 15 No No No
Yes, prohibits the mainte-
nance of a unfrozen fertil-
ized pre-embryo past 14 
days
Yes
New Jersey
C.26:2Z-1 et seq.; 
C.2C:11A-1
Yes No Yes No No
New Mexico
§24-9A-1, 3, 5 No No No
Yes, prohibits research on a 
fetus/embryo born or ex-
tracted alive, only applies to 
in vitro fertilized embryos 
post-implantation
Yes, prohibits abor-
tion for the purpose 
of selling the fetus to 
researchers
New York 
Public Health Law 
Article 2, Title 5A
Yes, permits research 
on adult and embry-
onic stem cells from 
any source
No No   
North Dakota
§14-02.2-01, 2; 2003 
HB 1424
No
Yes, prohibits research on 
a living/non-living em-
bryo or fetus
Yes, requires consent 
to conduct research on 
a nonliving fetus or 
embryo other than 
from an abortion
Yes, prohibits research on a 
fetus born or extracted 
alive; cloned embryos
Yes, prohibits the 
sale of a fetus to be 
used for illegal pur-
poses
Ohio
§2919.14 No
Yes, prohibits research on 
a living/non-living em-
bryo or fetus
No No
Yes, prohibits sale of 
fetus or fetal remains 
from an abortion
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Oklahoma
63 §1-735 No
Yes, prohibits research on 
a fetus/embryo No No
Yes, prohibits sale of 
fetus or fetal remains
Pennsylvania
18 §§3203, 3216 No
Yes, prohibits research on 
a live embryo or fetus
Consideration may not 
be given to mothers 
consenting to research; 
in cases involving 
abortion, consent must 
be provided after 
decision to abort
No
Yes, consideration 
may not be given to 
mothers consenting 
to research or other 
transferring tissue 
except for expenses 
involved in actual 
retrieval, storage, etc.
Rhode Island
§11-54-1 No No Yes
Yes, prohibits research on a 
fetus/embryo born or ex-
tracted alive, only applies to 
in vitro fertilized embryos 
post-implantation
Yes, prohibits sale of 
neonate, embryo or 
fetus for illegal pur-
poses
South Dakota
§§34-14-16, 17, 20; 
34-23A-17
No
Yes, prohibits research on 
a living/non-living em-
bryo or fetus
No
Yes, prohibits research on 
embryo outside of a 
woman's body; research on 
cells or tissues derived from 
an embryo outside a 
woman's body
Yes, prohibits sale of 
embryo
Tennessee
§39-15-208 No No
Yes, consent required 
to conduct research on 
aborted fetus
No Yes, prohibits sale of aborted fetus
Texas Penal
Code §48.02 No No No No
Prohibits sale of 
fetus/fetal tissue
Utah
§§76-7-301, 310 No No No
Yes, prohibits research on a 
live fetus, fertilized embryo 
post-implantation1
Yes, prohibits sale of 
fetus/fetal tissue; 
also prohibits sale of 
live unborn children, 
which is not defined, 
but are referred to in 
abortion statute1
Virginia
§32.1-162.32-2 No No No
May prohibit research on a 
cloned embryo or fetus2
Yes, prohibits ship-
ping or receiving of 
the product of human 
cloning for commer-
ce2
Wyoming
§35-6-115 No No No No
Yes, prohibits sale, 
distribution or dona-
tion of live or viable 
aborted child, de-
fined to include 
embryos, for experi-
mentation
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